## Identification of separable cognitive factors in schizoph

Schizophrenia Research 72, 29-39 DOI: 10.1016/j.schres.2004.09.007

Citation Report

#	Article	IF	CITATIONS
1	NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophrenia Research, 2004, 72, 11-19.	1.1	106
2	The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophrenia Research, 2004, 72, 1-3.	1.1	242
3	Stimulating development of new drugs to improve cognition in schizophrenia. Current Psychosis & Therapeutics Reports, 2005, 3, 68-73.	0.1	1
4	Factors Mediating Cognitive Deficits and Psychopathology Among Siblings of Individuals With Schizophrenia. Schizophrenia Bulletin, 2005, 32, 525-537.	2.3	90
5	EditorialModeling Negative Symptoms: What's Missing?. Schizophrenia Bulletin, 2005, 32, 403-404.	2.3	4
6	Distinguishing Separable Domains of Cognition in Human and Animal Studies: What Separations Are Optimal for Targeting Interventions? A Summary of Recommendations From Breakout Group 2 at the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference, Schizophrenia Bulletin, 2005, 31, 870-874.	2.3	50
7	Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia. Schizophrenia Bulletin, 2005, 31, 830-853.	2.3	105
9	Synthesizing Schizophrenia: A Bottom-Up, Symptomatic Approach. Schizophrenia Bulletin, 2005, 31, 854-864.	2.3	40
11	Social Cognition in Schizophrenia: Recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference. Schizophrenia Bulletin, 2005, 31, 882-887.	2.3	377
12	A pilot study of social cognition and interaction training (SCIT) for schizophrenia. Schizophrenia Research, 2005, 80, 357-359.	1.1	145
13	Cognition in Schizophrenia: Impairments, Determinants, and Functional Importance. Psychiatric Clinics of North America, 2005, 28, 613-633.	0.7	207
14	The Primacy of Cognition in Schizophrenia American Psychologist, 2005, 60, 229-242.	3.8	295
15	Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia. Drugs, 2006, 66, 1465-1473.	4.9	27
16	Neuropsychological Performance in First-Episode Adolescents with Schizophrenia: A Comparison with First-Episode Adults and Adolescent Control Subjects. Biological Psychiatry, 2006, 60, 463-471.	0.7	95
17	Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia. Schizophrenia Research, 2006, 82, 153-162.	1.1	244
18	The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery. Schizophrenia Research, 2006, 82, 39-49.	1.1	34
19	Neurocognitive performance and functional disability in the psychosis prodrome. Schizophrenia Research, 2006, 84, 100-111.	1.1	232
20	A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophrenia Research, 2006, 85, 20-29.	1.1	96

#	Article	IF	CITATIONS
21	Associating functional recovery with neurocognitive profiles identified using partially ordered classification models. Schizophrenia Research, 2006, 85, 40-48.	1.1	18
22	Associations between olfactory identification and verbal memory in patients with schizophrenia, first-degree relatives, and non-psychiatric controls. Schizophrenia Research, 2006, 86, 154-166.	1.1	32
23	Effects of phencyclidine on spatial learning and memory: Nitric oxide-dependent mechanisms. Behavioural Brain Research, 2006, 171, 147-153.	1.2	44
24	Phencyclidine affects memory in a nitric oxide-dependent manner: Working and reference memory. Behavioural Brain Research, 2006, 174, 49-55.	1.2	48
25	Neurobiology of Schizophrenia. Neuron, 2006, 52, 139-153.	3.8	617
27	Neuropsychological performance at the age of 13 years and adult schizophreniform disorder. British Journal of Psychiatry, 2006, 189, 463-464.	1.7	71
28	Impaired control of visual attention in schizophrenia Journal of Abnormal Psychology, 2006, 115, 266-275.	2.0	80
29	Translating basic attentional paradigms to schizophrenia research: Reconsidering the nature of the deficits. Development and Psychopathology, 2006, 18, 831-51.	1.4	27
30	Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. Journal of the International Neuropsychological Society, 2006, 12, 34-44.	1.2	26
31	Procedural Memory Predicts Social Skills in Persons With Schizophrenia. Journal of Nervous and Mental Disease, 2006, 194, 625-627.	0.5	8
32	Subtyping schizophrenia: implications for genetic research. Molecular Psychiatry, 2006, 11, 815-836.	4.1	222
33	The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology, 2006, 187, 312-320.	1.5	117
34	The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps?. Neurotoxicity Research, 2006, 10, 211-220.	1.3	144
35	Sensorimotor and cognitive slowing in schizophrenia as measured by the Symbol Digit Substitution Test. Journal of Psychiatric Research, 2006, 40, 200-206.	1.5	45
36	Distinguishing Neurocognitive Functions in Schizophrenia Using Partially Ordered Classification Models. Schizophrenia Bulletin, 2006, 32, 679-691.	2.3	32
37	The Consortium on the Genetics of Schizophrenia: Neurocognitive Endophenotypes. Schizophrenia Bulletin, 2006, 33, 49-68.	2.3	332
38	Human Cognition Assessment in Drug Research. Current Pharmaceutical Design, 2006, 12, 2525-2539.	0.9	21
39	Social Cognition Deficit in Schizophrenia: Accounting for Pragmatic Deficits in Communication Abilities?. Current Psychiatry Reviews, 2006, 2, 309-315.	0.9	19

#	Article	IF	CITATIONS
40	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology, 2006, 31, 2033-2046.	2.8	408
41	Integrated Psychological Therapy (IPT) for Schizophrenia: Is It Effective?. Schizophrenia Bulletin, 2006, 32, S81-S93.	2.3	212
42	Clinicians' Concepts of the Cognitive Deficits of Schizophrenia. Schizophrenia Bulletin, 2007, 33, 648-651.	2.3	11
43	Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia. Schizophrenia Bulletin, 2007, 33, 1120-1130.	2.3	168
44	A Meta-Analysis of Cognitive Remediation in Schizophrenia. American Journal of Psychiatry, 2007, 164, 1791-1802.	4.0	1,017
45	Acute Effects of the Ampakine Farampator on Memory and Information Processing in Healthy Elderly Volunteers. Neuropsychopharmacology, 2007, 32, 1272-1283.	2.8	98
46	Psychomotor Slowing in Schizophrenia. Schizophrenia Bulletin, 2007, 33, 1038-1053.	2.3	204
47	Measurement Issues in the Use of Cognitive Neuroscience Tasks in Drug Development for Impaired Cognition in Schizophrenia: A Report of the Second Consensus Building Conference of the CNTRICS Initiative. Schizophrenia Bulletin, 2007, 34, 613-618.	2.3	45
48	Less Unique Variance Than Meets the Eye: Overlap Among Traditional Neuropsychological Dimensions in Schizophrenia. Schizophrenia Bulletin, 2007, 34, 423-434.	2.3	41
49	New Paradigms for Treatment Development. Schizophrenia Bulletin, 2007, 33, 1093-1099.	2.3	18
50	Toward an Integrative Perspective on Hippocampal Function: From the Rapid Encoding of Experience to Adaptive Behavior. Reviews in the Neurosciences, 2007, 18, 253-81.	1.4	125
51	A Sensitizing Regimen of Amphetamine Impairs Visual Attention in the 5-Choice Serial Reaction Time Test: Reversal by a D1 Receptor Agonist Injected into the Medial Prefrontal Cortex. Neuropsychopharmacology, 2007, 32, 1122-1132.	2.8	69
52	Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia. Central Nervous System Agents in Medicinal Chemistry, 2007, 7, 269-288.	0.5	9
53	Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. American Journal of Psychiatry, 2007, 164, 1061-1071.	4.0	234
54	Sudden Glory Revisited: Cognitive Contents of Hypomania. Psychotherapy and Psychosomatics, 2007, 76, 278-288.	4.0	19
55	Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. American Journal of Psychiatry, 2007, 164, 1585-1592.	4.0	111
56	Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia. Schizophrenia Bulletin, 2007, 33, 1100-1119.	2.3	205
57	North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal Schizophrenia Research. Schizophrenia Bulletin, 2007, 33, 665-672.	2.3	258

#	Article	IF	CITATIONS
58	How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment?. Schizophrenia Bulletin, 2007, 33, 912-920.	2.3	332
59	The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 173-186.	0.0	3
60	How Neurocognition and Social Cognition Influence Functional Change During Community-Based Psychosocial Rehabilitation for Individuals with Schizophrenia. Schizophrenia Bulletin, 2007, 33, 1247-1256.	2.3	155
61	Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function. Schizophrenia Bulletin, 2007, 34, 93-108.	2.3	23
62	Cognitive heterogeneity in schizophrenia. Current Opinion in Psychiatry, 2007, 20, 268-272.	3.1	144
63	Criterion B (social dysfunction) in persons with schizophrenia: the puzzle. Current Opinion in Psychiatry, 2007, 20, 582-587.	3.1	14
64	Psychomotor and Memory Effects of Haloperidol, Olanzapine, and Paroxetine in Healthy Subjects After Short-Term Administration. Journal of Clinical Psychopharmacology, 2007, 27, 15-21.	0.7	34
66	Schizotypal disorder and schizophrenia: A profile analysis of neuropsychological functioning in Japanese patients. Journal of the International Neuropsychological Society, 2007, 13, 672-82.	1.2	22
67	Visual-spatial learning and memory in schizotypal personality disorder: Continued evidence for the importance of working memory in the schizophrenia spectrumâ^†. Archives of Clinical Neuropsychology, 2007, 22, 109-116.	0.3	26
68	Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. European Psychiatry, 2007, 22, 365-370.	0.1	31
70	Overview of Animal Models of Schizophrenia. Current Protocols in Neuroscience, 2007, 39, Unit 9.24.	2.6	25
71	Stimulating the Development of Drug Treatments to Improve Cognition in Schizophrenia. Annual Review of Clinical Psychology, 2007, 3, 159-180.	6.3	75
72	The Course of Neurocognition and Social Functioning in Individuals at Ultra High Risk for Psychosis. Schizophrenia Bulletin, 2007, 33, 772-781.	2.3	139
73	Cognitive Functioning in the Schizophrenia Prodrome. Schizophrenia Bulletin, 2007, 33, 761-771.	2.3	202
74	The Palau Early Psychosis Study: Neurocognitive functioning in high-risk adolescents. Schizophrenia Research, 2007, 89, 299-307.	1.1	42
75	A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophrenia Research, 2007, 89, 211-224.	1.1	125
76	Structural analysis of the basal ganglia in schizophrenia. Schizophrenia Research, 2007, 89, 59-71.	1.1	124
77	Parietal lobe volume deficits in schizophrenia spectrum disorders. Schizophrenia Research, 2007, 89, 35-48.	1.1	89

#	Article	IF	CITATIONS
78	Social cognition in schizophrenia: Relationships with neurocognition and negative symptoms. Schizophrenia Research, 2007, 90, 316-324.	1.1	338
79	Factor analysis of neurocognitive tests in a large sample of schizophrenic probands, their siblings, and healthy controls. Schizophrenia Research, 2007, 94, 231-239.	1.1	46
80	Iowa Gambling Task in schizophrenia: A review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophrenia Research, 2007, 92, 74-84.	1.1	166
81	Factor analytic support for social cognition as a separable cognitive domain in schizophrenia. Schizophrenia Research, 2007, 93, 325-333.	1.1	94
82	Functional disintegration in paranoid schizophrenia using resting-state fMRI. Schizophrenia Research, 2007, 97, 194-205.	1.1	384
83	Social cognitive impairments in first episode psychosis. Schizophrenia Research, 2007, 95, 124-133.	1.1	111
84	NCAM1 and Neurocognition in Schizophrenia. Biological Psychiatry, 2007, 61, 902-910.	0.7	80
85	Adjudicating neurocognitive endophenotypes for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 242-249.	1.1	93
86	Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry, 2007, 12, 206-220.	4.1	241
87	Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Research, 2007, 1154, 154-162.	1.1	68
88	Cognitive dimensions in first-episode schizophrenia spectrum disorders. Journal of Psychiatric Research, 2007, 41, 968-977.	1.5	77
89	Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking. Cellular and Molecular Neurobiology, 2007, 27, 609-639.	1.7	60
90	Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotoxicity Research, 2008, 14, 71-78.	1.3	81
91	Better pharmacotherapy for schizophrenia: What does the future hold?. Current Psychiatry Reports, 2008, 10, 352-358.	2.1	25
92	Executive function and genetic predisposition to schizophrenia—the Maudsley family study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 285-293.	1.1	45
93	Neurocognitive endophenotypes for bipolar disorder. Bipolar Disorders, 2008, 10, 387-399.	1.1	67
94	Neuropsychological impairment in deficit vs. non-deficit schizophrenia. Journal of Psychiatric Research, 2008, 42, 930-937.	1.5	33
95	Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. Journal of Medicinal Chemistry, 2008, 51, 1077-1107.	2.9	51

#	Article	IF	CITATIONS
96	Voxel-based morphometry in schizophrenia: implications for neurodevelopmental connectivity models, cognition and affect. Expert Review of Neurotherapeutics, 2008, 8, 1049-1065.	1.4	61
97	Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. Schizophrenia Research, 2008, 100, 242-251.	1.1	128
98	A potential novel paradigm for testing digit-color synesthetic-like experiences in schizophrenia. Schizophrenia Research, 2008, 98, 329-330.	1.1	3
99	How to find the way out from four rooms? The learning of "chaining―associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophrenia Research, 2008, 99, 200-207.	1.1	34
100	Clinical global impression of cognition in schizophrenia (CGI-CogS): Reliability and validity of a co-primary measure of cognition. Schizophrenia Research, 2008, 106, 59-69.	1.1	75
101	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophrenia Research, 2008, 99, 139-148.	1.1	78
102	Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?. Schizophrenia Research, 2008, 99, 149-154.	1.1	39
103	General and social cognition in first episode schizophrenia: Identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. Schizophrenia Research, 2008, 99, 182-191.	1.1	92
104	A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophrenia Research, 2008, 101, 9-16.	1.1	59
105	Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 2008, 105, 86-94.	1.1	9
106	Temperament and character as schizophrenia-related endophenotypes in non-psychotic siblings. Schizophrenia Research, 2008, 104, 198-205.	1.1	113
107	Frontal release signs among patients with schizophrenia, their first-degree biological relatives, and non-psychiatric controls. Schizophrenia Research, 2008, 106, 275-280.	1.1	6
108	Predicting Schizophrenia Patients' Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures. Biological Psychiatry, 2008, 63, 505-511.	0.7	511
109	Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry, 2008, 64, 4-10.	0.7	172
110	Visual Perception and Its Impairment in Schizophrenia. Biological Psychiatry, 2008, 64, 40-47.	0.7	378
111	General and Specific Cognitive Deficits in Schizophrenia: Goliath Defeats David?. Biological Psychiatry, 2008, 64, 823-827.	0.7	232
112	Cognitive enhancing drugs for schizophrenia. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 145-150.	0.5	1
113	Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis. American Journal of Psychiatric Rehabilitation, 2008, 11, 144-163.	0.7	74

#	Article	IF	Citations
114	Serotonin depletion in the dorsal and ventral hippocampus: Effects on locomotor hyperactivity, prepulse inhibition and learning and memory. Neuropharmacology, 2008, 55, 1048-1055.	2.0	54
115	Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience, 2008, 155, 1021-1029.	1.1	88
116	Predictors of medication competence in schizophrenia patients. Psychiatry Research, 2008, 157, 47-52.	1.7	40
117	Analysis of cognitive performance in schizophrenia patients and healthy individuals with unsupervised clustering models. Psychiatry Research, 2008, 159, 167-179.	1.7	34
118	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Research, 2008, 159, 140-146.	1.7	49
119	Bleuler revisited: Psychomotor slowing in schizophrenia as part of a catatonic symptom cluster. Psychiatry Research, 2008, 161, 121-125.	1.7	17
120	Developing New Drugs for Schizophrenia: From Animals to the Clinic. , 2008, , 199-261.		18
122	A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behavioural Brain Research, 2008, 189, 152-158.	1.2	86
123	The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: A cross-sectional exploratory study. Clinical Therapeutics, 2008, 30, 684-692.	1.1	22
124	Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clinical Therapeutics, 2008, 30, 1565-1589.	1.1	62
125	Social cognition as a mediator of cognition and outcome among deaf and hearing people with schizophrenia. Schizophrenia Research, 2008, 105, 125-137.	1.1	28
126	Cognitive insight and verbal memory in first episode of psychosis. European Psychiatry, 2008, 23, 368-374.	0.1	69
127	Classifying Antipsychotic Agents. CNS Drugs, 2008, 22, 1047-1059.	2.7	15
128	Social Cognition Training for Individuals with Schizophrenia: Emerging Evidence. American Journal of Psychiatric Rehabilitation, 2008, 11, 205-252.	0.7	95
129	Social Cognition in Schizophrenia: An NIMH Workshop on Definitions, Assessment, and Research Opportunities. Schizophrenia Bulletin, 2008, 34, 1211-1220.	2.3	818
130	Seeing is remembering: Do deficits in closure affect visual memory recognition in schizophrenia?. Cognitive Neuropsychiatry, 2008, 13, 385-405.	0.7	6
131	The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. American Journal of Psychiatry, 2008, 165, 203-213.	4.0	1,863
133	Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia. American Journal of Psychiatry, 2008, 165, 82-89.	4.0	161

#	Article	IF	CITATIONS
134	The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization. American Journal of Psychiatry, 2008, 165, 214-220.	4.0	593
135	Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. World Psychiatry, 2008, 7, 22-28.	4.8	132
136	Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society, 2008, 14, 209-21.	1.2	41
137	Individual placement and support for individuals with recent-onset schizophrenia: Integrating supported education and supported employment Psychiatric Rehabilitation Journal, 2008, 31, 340-349.	0.8	188
138	Neurocognition as a Treatment Target in Schizophrenia. Focus (American Psychiatric Publishing), 2008, 6, 180-183.	0.4	2
139	Cognitive, clinical, and functional characteristics of verbally superior schizophrenia patients Neuropsychology, 2008, 22, 321-328.	1.0	34
140	Cognitive markers of short-term clinical outcome in first-episode psychosis. British Journal of Psychiatry, 2008, 193, 297-304.	1.7	44
141	Muscarinic Agonists for the Treatment of Cognition in Schizophrenia. CNS Spectrums, 2008, 13, 985-996.	0.7	47
142	Zebrafish: An in vivo model for the study of neurological diseases. Neuropsychiatric Disease and Treatment, 2008, 4, 567.	1.0	159
143	Cognição social na esquizofrenia: um enfoque em habilidades teoria da mente. Revista De Psiquiatria Do Rio Grande Do Sul, 2009, 31, .	0.3	0
144	Cognitive Deficits in Schizophrenia. , 2009, , 1101-1109.		1
145	Premorbid cognitive deficits in young relatives of schizophrenia patients. Frontiers in Human Neuroscience, 2009, 3, 62.	1.0	63
146	Neurocognition in first-episode schizophrenia: A meta-analytic review Neuropsychology, 2009, 23, 315-336.	1.0	960
147	Impaired conscious and preserved unconscious inhibitory processing in recent onset schizophrenia. Psychological Medicine, 2009, 39, 907-916.	2.7	52
148	Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis. Psychological Medicine, 2009, 39, 1799-1808.	2.7	31
149	Disruption of Mesolimbic Regulation of Prefrontal Cholinergic Transmission in an Animal Model of Schizophrenia and Normalization by Chronic Clozapine Treatment. Neuropsychopharmacology, 2009, 34, 2710-2720.	2.8	18
150	Classification of schizophrenia. Part 2: the nonsense of mental health illness. British Journal of Nursing, 2009, 18, 1228-1232.	0.3	1
151	Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem. Schizophrenia Bulletin, 2009, 35, 403-414.	2.3	121

#	Article	IF	CITATIONS
152	Executive Functions and the Obsessive-Compulsive Disorder: On the Importance of Subclinical Symptoms and Other Concomitant Factors. Archives of Clinical Neuropsychology, 2009, 24, 585-598.	0.3	47
153	Role of processing speed and premorbid IQ on visual recognition in patients with schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 302-311.	0.8	10
154	Cognitive profiles of healthy siblings of schizophrenia patients: Application of the cognitive domains of the MATRICS consensus battery. World Journal of Biological Psychiatry, 2009, 10, 452-460.	1.3	15
155	Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. , 2009, 122, 150-202.		285
156	Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia. Psychiatry Research - Neuroimaging, 2009, 173, 88-93.	0.9	27
157	Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology, 2009, 202, 315-328.	1.5	127
158	Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology, 2009, 202, 259-273.	1.5	40
159	Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 2009, 9, 44.	1.1	57
160	Suicidality Connected with Mentalizing Anomalies in Schizophrenia. Annals of the New York Academy of Sciences, 2009, 1167, 207-211.	1.8	12
162	Modeling cognitive endophenotypes of schizophrenia in mice. Trends in Neurosciences, 2009, 32, 347-358.	4.2	133
163	Absence of established sex differences in patients with schizophrenia on a two-dimensional object array task. Psychiatry Research, 2009, 166, 158-165.	1.7	9
164	The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?. Molecular and Cellular Neurosciences, 2009, 42, 438-447.	1.0	79
165	Schizophrenia and epilepsy: Is there a shared susceptibility?. Neuroscience Research, 2009, 63, 227-235.	1.0	121
166	Bridging the gap between schizophrenia and psychotic mood disorders: Relating neurocognitive deficits to psychopathology. Schizophrenia Research, 2009, 107, 69-75.	1.1	56
167	Psychomotor planning is deficient in recent-onset schizophrenia. Schizophrenia Research, 2009, 107, 294-302.	1.1	35
168	Commentary on O'Halloran et al. Schizophrenia Research, 2009, 107, 327-329.	1.1	2
169	Psychopathology and cognition in divergent functional outcomes in schizophrenia. Schizophrenia Research, 2009, 109, 46-51.	1.1	19
170	Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis. Schizophrenia Research, 2009, 113, 189-199.	1.1	462

#	Article	IF	CITATIONS
171	Lurasidone: a new drug in development for schizophrenia. Expert Opinion on Investigational Drugs, 2009, 18, 1715-1726.	1.9	115
172	Explicit identification and implicit recognition of facial emotions: II. Core domains and relationships with general cognition. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 278-291.	0.8	98
173	Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations Psychological Bulletin, 2009, 135, 157-171.	5.5	241
174	Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models. Neuropsychopharmacology, 2009, 34, 74-89.	2.8	301
175	CNTRICS Final Task Selection: Control of Attention. Schizophrenia Bulletin, 2009, 35, 182-196.	2.3	84
176	Disturbances in the spontaneous attribution of social meaning in schizophrenia. Psychological Medicine, 2009, 39, 635-643.	2.7	50
177	The predictive value of measures of social cognition for community functioning in schizophrenia: Implications for neuropsychological assessment. Journal of the International Neuropsychological Society, 2009, 15, 239-247.	1.2	78
178	Neuroimaging Studies of Substance Abuse in Schizophrenia. Current Psychiatry Reviews, 2009, 5, 250-260.	0.9	3
179	Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists. Current Pharmaceutical Design, 2010, 16, 309-322.	0.9	51
180	Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders. Current Topics in Medicinal Chemistry, 2010, 10, 187-206.	1.0	37
182	Are working memory deficits in bipolar disorder markers for psychosis?. Neuropsychology, 2010, 24, 244-254.	1.0	29
183	No association between prepulse inhibition of the startle reflex and neuropsychological deficit in chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 609-615.	1.8	9
184	Deficient maturation of aspects of attention and executive functions in early onset schizophrenia. European Child and Adolescent Psychiatry, 2010, 19, 773-786.	2.8	25
185	Promise and Pitfalls of Animal Models of Schizophrenia. Current Psychiatry Reports, 2010, 12, 327-334.	2.1	26
186	Evidence of association of KIBRA genotype with episodic memory in families of psychotic patients and controls. Journal of Psychiatric Research, 2010, 44, 795-798.	1.5	31
187	Grammatical processing in schizophrenia: Evidence from morphology. Neuropsychologia, 2010, 48, 262-269.	0.7	20
188	Metabotropic glutamate receptor 7: At the interface of cognition and emotion. European Journal of Pharmacology, 2010, 639, 123-131.	1.7	75
189	Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clinical Therapeutics, 2010, 32, S3-S20.	1.1	86

#	Article	IF	CITATIONS
190	Neurocognitive markers of psychosis in bipolar disorder: A meta-analytic study. Journal of Affective Disorders, 2010, 127, 1-9.	2.0	125
191	The impact of a genomeâ€wide supported psychosis variant in the <i>ZNF804A</i> gene on memory function in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1459-1464.	1.1	57
192	Stochastic dynamics of stimulus encoding in schizophrenia: Theory, testing, and application. Journal of Mathematical Psychology, 2010, 54, 90-108.	1.0	18
193	Assessing cognitive function in clinical trials of schizophrenia. Neuroscience and Biobehavioral Reviews, 2010, 34, 1161-1177.	2.9	152
194	Research Review: attention bias modification (ABM): a novel treatment for anxiety disorders. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2010, 51, 859-870.	3.1	459
195	The antecedents of nonâ€affective psychosis in a birthâ€cohort, with a focus on measures related to cognitive ability, attentional dysfunction and speech problems. Acta Psychiatrica Scandinavica, 2010, 121, 273-279.	2.2	26
196	Is there an association between neurocognitive performance and medication adherence in first episode psychosis?. Microbial Biotechnology, 2010, 4, 189-195.	0.9	21
197	The International Society for Bipolar Disorders–Battery for Assessment of Neurocognition (ISBDâ€BANC). Bipolar Disorders, 2010, 12, 351-363.	1.1	218
198	Neurocognition. , 0, , 97-119.		2
199	Exploration of a genomic expression and pathway analysis approach to neurocognitive performance: preliminary findings. Neurobehavioral HIV Medicine, 2010, , 23.	2.0	0
200	Factor Structure of the Neurocognitive Tests: An Application of the Confirmative Factor Analysis in Stabilized Schizophrenia Patients. Journal of Korean Medical Science, 2010, 25, 276.	1.1	11
201	Neurobiology and etiology of primary schizophrenia: current status. , 2010, , 3-15.		3
202	Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis. Schizophrenia Bulletin, 2010, 36, 43-47.	2.3	38
203	Factor Structures of the Neurocognitive Assessments and Familial Analysis in First-Episode Schizophrenia Patients, Their Relatives and Controls. Australian and New Zealand Journal of Psychiatry, 2010, 44, 109-119.	1.3	21
204	Investigating cognitive deficits and symptomatology across pre-morbid adjustment patterns in first-episode psychosis. Psychological Medicine, 2010, 40, 749-759.	2.7	26
205	The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. International Journal of Neuropsychopharmacology, 2010, 13, 1035-1051.	1.0	70
206	Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-NaÃ⁻ve First-Episode Schizophrenia Patients. Neuropsychobiology, 2010, 61, 79-86.	0.9	31
207	Cognitive Performance and Functional Competence as Predictors of Community Independence in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 381-387.	2.3	43

#	Article	IF	CITATIONS
208	New Opportunities in the Treatment of Cognitive Impairments Associated With Schizophrenia. Current Directions in Psychological Science, 2010, 19, 264-269.	2.8	7
209	Use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to Investigate Group and Gender Differences in Schizophrenia and Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2010, 44, 220-229.	1.3	63
210	Neurocognitive function in schizophrenia with comorbid posttraumatic stress disorder. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 737-751.	0.8	21
211	Cognitive function, social functioning and quality of life in first-episode psychosis: A 1-year longitudinal study. International Journal of Psychiatry in Clinical Practice, 2010, 14, 33-40.	1.2	15
212	Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium <subtitle>Relationship to Family History and Conversion to Psychosis</subtitle> <alt-title>Neuropsychology of Prodrome to Psychosis</alt-title> . Archives of General Psychiatry, 2010, 67, 578.	13.8	390
213	Declarative and nondeclarative memory in schizophrenia: What is impaired? What is spared?. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 1017-1027.	0.8	22
214	Programas de Rehabilitación Psicosocial en la Atención Comunitaria a las Personas con Psicosis. Clinica Y Salud, 2010, 21, 319-332.	0.3	6
215	Pharmacological Interventions. Key Issues in Mental Health, 2010, , 145-157.	0.6	1
216	Evaluating the Impact of Behavioral Healthcare Informatics. Computers in Health Care, 2010, , 181-193.	0.2	0
217	Models of Neurodevelopmental Abnormalities in Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 435-481.	0.8	60
218	Combined Treatment Approaches: Overview and Empirical Results. Key Issues in Mental Health, 2010, , 85-103.	0.6	2
219	Integrated Psychological Therapy and Integrated Neurocognitive Therapy. Key Issues in Mental Health, 2010, , 118-144.	0.6	20
220	Static and Dynamic Cognitive Deficits in Childhood Preceding Adult Schizophrenia: A 30-Year Study. American Journal of Psychiatry, 2010, 167, 160-169.	4.0	483
221	Toward a Model of Cognitive Insight in First-Episode Psychosis: Verbal Memory and Hippocampal Structure. Schizophrenia Bulletin, 2010, 36, 1040-1049.	2.3	65
222	Definition and Measurement of Neurocognition and Social Cognition. Key Issues in Mental Health, 2010, , 1-22.	0.6	8
223	Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology. Current Pharmaceutical Design, 2010, 16, 323-343.	0.9	182
224	Translating Experimental Neuroscience into Treatment of Eating Disorders: Two Examples. Current Topics in Behavioral Neurosciences, 2010, 6, 253-268.	0.8	2
225	Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Review of Neurotherapeutics, 2010, 10, 1347-1359.	1.4	152

#	Article	IF	CITATIONS
226	Disruption of Performance in the Five-Choice Serial Reaction Time Task Induced By Administration of N-Methyl-D-Aspartate Receptor Antagonists: Relevance to Cognitive Dysfunction in Schizophrenia. Biological Psychiatry, 2010, 68, 5-16.	0.7	113
229	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). Schizophrenia Research, 2010, 116, 243-251.	1.1	55
230	Executive function in schizophrenia: Influence of substance use disorder history. Schizophrenia Research, 2010, 118, 34-40.	1.1	19
231	Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia. Schizophrenia Research, 2010, 122, 156-163.	1.1	36
232	Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation. Schizophrenia Research, 2010, 118, 189-200.	1.1	51
233	Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophrenia Research, 2010, 120, 191-198.	1.1	20
234	An investigation of 3 neurocognitive subtypes in schizophrenia. Schizophrenia Research, 2010, 121, 32-38.	1.1	24
235	The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research, 2010, 121, 24-31.	1.1	76
236	Language, motor and speed of processing deficits in adolescents with subclinical psychotic symptoms. Schizophrenia Research, 2010, 123, 71-76.	1.1	77
237	Disorganization and reality distortion in schizophrenia: A meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophrenia Research, 2010, 121, 1-14.	1.1	143
238	Neuropsychological profiles in individuals at clinical high risk for psychosis: Relationship to psychosis and intelligence. Schizophrenia Research, 2010, 123, 188-198.	1.1	107
239	Attention Deficits and Response to Drug Therapy in Patients With Treatment-Resistant Schizophrenia: Results Through Confirmatory Factorial Analysis. Revista De PsiquiatrÃa Y Salud Mental (English) Tj ETQq1 1 0.78	4 <b>301</b> 24 rgBT	/@verlock 1
240	Cognitive Complaints in Schizophrenia: Relationship With Insight and Other Cognitive Measures. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2010, 3, 55-60.	0.2	6
241	Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 211-218.	2.3	165
242	Reduced prefrontal activation during Tower of London in first-episode schizophrenia: A multi-channel near-infrared spectroscopy study. Neuroscience Letters, 2010, 478, 136-140.	1.0	31
243	Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Research Bulletin, 2010, 83, 162-176.	1.4	31
244	Effects on cognitive functioning after olanzapine–ziprasidone crossover in recent-onset schizophrenia. European Neuropsychopharmacology, 2010, 20, 907-912.	0.3	9
245	The Hippocampal Formation in Schizophrenia. American Journal of Psychiatry, 2010, 167, 1178-1193.	4.0	507

	CITATION R	CITATION REPORT	
#	Article	IF	CITATIONS
246	Neuropsychology of Treatment-Resistant Schizophrenia. Advances in Biological Psychiatry, 2010, , 33-51.	0.2	3
247	Animal Models of Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 391-433.	0.8	75
248	Behavioral Neurobiology of Schizophrenia and Its Treatment. Current Topics in Behavioral Neurosciences, 2010, , .	0.8	8
249	A Meta-Analysis of Neuropsychological Functioning in Patients with Early Onset Schizophrenia and Pediatric Bipolar Disorder. Journal of Clinical Child and Adolescent Psychology, 2011, 40, 266-280.	2.2	65
250	Reducing Prefrontal Gamma-Aminobutyric Acid Activity Induces Cognitive, Behavioral, and Dopaminergic Abnormalities That Resemble Schizophrenia. Biological Psychiatry, 2011, 69, 432-441.	0.7	147
251	A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. Biological Psychiatry, 2011, 69, 442-449.	0.7	155
252	Schizophrenia: Treatment Targets Beyond Monoamine Systems. Annual Review of Pharmacology and Toxicology, 2011, 51, 189-209.	4.2	56
253	Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia Research, 2011, 126, 257-264.	1.1	162
254	Duration of untreated psychosis is associated with orbital–frontal grey matter volume reductions in first episode psychosis. Schizophrenia Research, 2011, 125, 13-20.	1.1	84
255	PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: Implications for the treatment of negative symptoms in schizophrenia. Schizophrenia Research, 2011. 125. 88-92.	1.1	29
256	Cognition at illness onset as a predictor of later functional outcome in early psychosis: Systematic review and methodological critique. Schizophrenia Research, 2011, 125, 221-235.	1.1	159
257	The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study. Schizophrenia Research, 2011, 126, 124-131.	1.1	204
258	Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. Schizophrenia Research, 2011, 131, 174-183.	1.1	28
259	Medial prefrontal cortical synapsin II knock-down induces behavioral abnormalities in the rat: Examining synapsin II in the pathophysiology of schizophrenia. Schizophrenia Research, 2011, 130, 250-259.	1.1	24
260	Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: A prospective study in a real-world setting. Schizophrenia Research, 2011, 133, 223-231.	1.1	57
261	Reliability of the Chinese VALPAR Pro3000 Modular Assessment System for Assessing Persons with Mental Illness. Hong Kong Journal of Occupational Therapy, 2011, 21, 50-55.	0.2	1
263	The role of NR4A transcription factors in memory formation. Brain Research Bulletin, 2011, 85, 21-29.	1.4	111
264	Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio). Behavioural Brain Research, 2011, 224, 135-139.	1.2	81

щ		15	CITATIONS
#	ARTICLE Semantic fluency and executive functions as candidate endophenotypes for the early diagnosis of	IF	CITATIONS
265	schizophrenia in Han Chinese. Neuroscience Letters, 2011, 502, 173-177.	1.0	29
266	Declarative memory deficits and schizophrenia: Problems and prospects. Neurobiology of Learning and Memory, 2011, 96, 544-552.	1.0	41
267	Contribution of specific cognitive dysfunction to people with schizotypal personality. Psychiatry Research, 2011, 186, 71-75.	1.7	14
269	Spanish Validation Of the Brief Assessment in Cognition in Schizophrenia (Bacs) in Patients With Schizophrenia and Healthy Controls. European Psychiatry, 2011, 26, 69-73.	0.1	62
270	Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: A prospective controlled study in a real-world setting. European Psychiatry, 2011, 26, 276-283.	0.1	24
271	Cognition dopamine and bioactive lipids in schizophrenia. Frontiers in Bioscience - Scholar, 2011, S3, 298-330.	0.8	46
272	Phencyclidine disturbs relational memory in the transitive inference task. Behavioural Pharmacology, 2011, 22, 262-265.	0.8	3
273	Experimental Pain Hypersensitivity in Schizophrenic Patients. Clinical Journal of Pain, 2011, 27, 790-795.	0.8	27
275	Processing Speed and Working Memory Span: Their Differential Role in Superficial and Deep Memory Processes in Schizophrenia. Journal of the International Neuropsychological Society, 2011, 17, 485-493.	1.2	12
277	Crystallized verbal skills in schizophrenia: Relationship to neurocognition, symptoms, and functional status Neuropsychology, 2011, 25, 784-791.	1.0	9
279	Animal Model for Schizophrenia That Reflects Gene-Environment Interactions. Biological and Pharmaceutical Bulletin, 2011, 34, 1364-1368.	0.6	32
280	Domains of cognitive impairment in bipolar disorder: commentary on "The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC)â€: Bipolar Disorders, 2011, 13, 217-218.	1.1	3
281	Animal models of schizophrenia. British Journal of Pharmacology, 2011, 164, 1162-1194.	2.7	613
282	Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatrica Scandinavica, 2011, 123, 165-174.	2.2	134
283	Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice. Genes, Brain and Behavior, 2011, 10, 720-733.	1.1	81
284	The MATRICS Consensus Cognitive Battery in Patients with Bipolar I Disorder. Neuropsychopharmacology, 2011, 36, 1587-1592.	2.8	163
285	Thalamic morphology in schizophrenia and schizoaffective disorder. Journal of Psychiatric Research, 2011, 45, 378-385.	1.5	46
286	Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacology Biochemistry and Behavior, 2011, 99, 164-189.	1.3	46

		CITATION R	EPORT	
#	Article		IF	CITATIONS
287	Translating cognition from animals to humans. Biochemical Pharmacology, 2011, 81, 1	356-1366.	2.0	123
288	The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recogn deficits in the rat. Psychopharmacology, 2011, 214, 269-283.	nition memory	1.5	74
289	Recent developments in neuropsychological endophenotypes for schizophrenia: Develo MATRICS battery, liability syndromes and the near future. Science Bulletin, 2011, 56, 3		1.7	1
290	Pain insensitivity in schizophrenia. Douleur Et Analgesie, 2011, 24, 152-159.		0.2	0
291	The relationship between neurocognition and social cognition with functional outcome schizophrenia: A meta-analysis. Neuroscience and Biobehavioral Reviews, 2011, 35, 573	25 in 3-588.	2.9	1,489
292	Visual Context Processing Deficits in Schizophrenia: Effects of Deafness and Disorganiz Schizophrenia Bulletin, 2011, 37, 716-726.	zation.	2.3	39
294	Insight in Psychosis: Relationship With Neurocognition, Social Cognition and Clinical Sy Depends on Phase of Illness. Schizophrenia Bulletin, 2011, 37, 29-37.	ymptoms	2.3	86
295	Effectiveness of Integrated Psychological Therapy (IPT) for Schizophrenia Patients: A Re Schizophrenia Bulletin, 2011, 37, S71-S79.	esearch Update.	2.3	154
296	What Is It like to Be a Person with Schizophrenia in the Social World? A First-Person Per on Schizophrenic Dissociality – Part 1: State of the Art. Psychopathology, 2011, 44, 2	rspective Study 172-182.	1.1	41
297	The emerging biology of delusions. Psychological Medicine, 2011, 41, 7-13.		2.7	21
298	Neurocognitive prediction of illness knowledge after psychoeducation in schizophrenia from the Munich COCPIP study. Psychological Medicine, 2011, 41, 533-544.	: results	2.7	22
299	Social Cognition as a Mediator Variable Between Neurocognition and Functional Outco Schizophrenia: Empirical Review and New Results by Structural Equation Modeling. Sch Bulletin, 2011, 37, S41-S54.		2.3	404
300	Neurocognitive Predictors of Work Outcome in Recent-Onset Schizophrenia. Schizoph 2011, 37, S33-S40.	renia Bulletin,	2.3	256
301	Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a study. Psychological Medicine, 2011, 41, 163-173.	meta-analytical	2.7	198
302	Cognitive Factor Structure and Invariance in People With Schizophrenia, Their Unaffect and Controls. Schizophrenia Bulletin, 2011, 37, 1157-1167.	ed Siblings,	2.3	72
303	Bifactor and item response theory analyses of interviewer report scales of cognitive imp schizophrenia Psychological Assessment, 2011, 23, 245-261.	pairment in	1.2	45
304	Comparative effects of different test day challenges on performance in the 5-choice set time task Behavioral Neuroscience, 2011, 125, 764-774.	rial reaction	0.6	46
305	A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicia Schizophrenia Bulletin, 2011, 37, 538-545.	ins.	2.3	77

#	Article	IF	CITATIONS
306	Cognitive Functioning in Schizophrenia and Co-occurring Substance Use Disorder: Where Do We Go From Here?. Journal of Dual Diagnosis, 2012, 8, 48-49.	0.7	5
307	Are Cardiovascular Risk Factors Associated with Verbal Learning and Memory Impairment in Patients with Schizophrenia? A Cross-Sectional Study. Cardiovascular Psychiatry and Neurology, 2012, 2012, 1-8.	0.8	11
308	Reading Times and Adaptive Styles among Patients Diagnosed with Psychosis as Assessed by the Serial Color-Word Test. Perceptual and Motor Skills, 2012, 114, 3-15.	0.6	0
309	Cardiac Responses during Picture Viewing in Young Male Patients with Schizophrenia. Cardiovascular Psychiatry and Neurology, 2012, 2012, 1-11.	0.8	3
310	Comparing Retrospective Reports to Real-Time/Real-Place Mobile Assessments in Individuals With Schizophrenia and a Nonclinical Comparison Group. Schizophrenia Bulletin, 2012, 38, 396-404.	2.3	87
311	Cognitive Functioning in Prodromal Psychosis. Archives of General Psychiatry, 2012, 69, 562-71.	13.8	567
312	Emotion Effects on Attention, Amygdala Activation, and Functional Connectivity in Schizophrenia. Schizophrenia Bulletin, 2012, 38, 967-980.	2.3	91
313	Clinical, Functional, and Intertask Correlations of Measures Developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophrenia Bulletin, 2012, 38, 144-152.	2.3	83
314	The puzzle of schizophrenia: Tracking the core role of cognitive deficits. Development and Psychopathology, 2012, 24, 529-536.	1.4	35
315	Paradoxical Cognitive Capacities in Dual Diagnosis Schizophrenia: The Quest for Explanatory Factors. Journal of Dual Diagnosis, 2012, 8, 35-47.	0.7	22
316	Cognitive Deficits in Schizophrenia and Alcoholism: A Review of the Evidence and Findings on the Effects of Treatment on Cognitive Functioning in Patients With Dual Diagnoses. Journal of Dual Diagnosis, 2012, 8, 205-217.	0.7	5
317	The causal relationships between neurocognition, social cognition and functional outcome over time in schizophrenia: a latent difference score approach. Psychological Medicine, 2012, 42, 2287-2299.	2.7	109
319	Treating Impaired Cognition in Schizophrenia. Current Pharmaceutical Biotechnology, 2012, 13, 1587-1594.	0.9	38
320	Neurocognition and Cognitive Biases in Schizophrenia. Journal of Nervous and Mental Disease, 2012, 200, 724-727.	0.5	12
323	Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia. Schizophrenia Research, 2012, 142, 122-128.	1.1	21
324	Dedifferentiation and substitute strategy: Deconstructing the processing-speed impairment in schizophrenia. Schizophrenia Research, 2012, 142, 129-136.	1.1	23
325	Clinical correlates associated with cognitive dysfunction in people with schizophrenia. Psychiatry and Clinical Neurosciences, 2012, 66, 491-498.	1.0	20
326	Homocysteine and cognition in first-episode psychosis patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 557-564.	1.8	51

#	Article	IF	CITATIONS
327	A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. European Neuropsychopharmacology, 2012, 22, 469-481.	0.3	40
328	The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry, 2012, 27, 275-280.	0.1	41
329	Stigma as a predictor of insight in schizophrenia. Psychiatry Research, 2012, 198, 187-193.	1.7	26
330	Theory of mind and context processing in schizophrenia: The role of cognitive flexibility. Psychiatry Research, 2012, 200, 184-192.	1.7	58
331	Schizotypal traits and neurocognitive functioning among nonclinical young adults. Psychiatry Research, 2012, 200, 635-640.	1.7	14
332	Cognitive and social cognitive predictors of change in objective versus subjective quality-of-life in rehabilitation for schizophrenia. Psychiatry Research, 2012, 200, 102-107.	1.7	20
333	Relationships Between Behavioral Syndromes and Cognitive Domains in Alzheimer Disease: The Impact of Mood and Psychosis. American Journal of Geriatric Psychiatry, 2012, 20, 994-1000.	0.6	49
334	Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers. Expert Opinion on Investigational Drugs, 2012, 21, 7-14.	1.9	5
336	Using Contemporary Technologies in the Assessment and Treatment of Serious Mental Illness. American Journal of Psychiatric Rehabilitation, 2012, 15, 357-376.	0.7	38
337	Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology, 2012, 62, 1564-1573.	2.0	111
338	NMDA receptors, cognition and schizophrenia $\hat{a} \in$ Testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology, 2012, 62, 1401-1412.	2.0	165
339	Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased. Neuropharmacology, 2012, 62, 1432-1441.	2.0	59
340	Social Cognition in Schizophrenia, Part 1: Performance Across Phase of Illness. Schizophrenia Bulletin, 2012, 38, 854-864.	2.3	354
341	Deficits in emotional learning and memory in an animal model of schizophrenia. Behavioural Brain Research, 2012, 233, 35-44.	1.2	34
342	Association of genetic variations in <i>DTNBP1</i> with cognitive function in schizophrenia patients and healthy subjects. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 841-849.	1.1	14
343	Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 39-79.	0.9	24
344	Severe Cross-Modal Object Recognition Deficits in Rats Treated Sub-Chronically with NMDA Receptor Antagonists are Reversed by Systemic Nicotine: Implications for Abnormal Multisensory Integration in Schizophrenia. Neuropsychopharmacology, 2012, 37, 2322-2331.	2.8	38
345	CHAPTER 4. Glutamatergic Approaches for the Treatment of Schizophrenia. RSC Drug Discovery Series, 2012, , 56-98.	0.2	1

#	Article	IF	CITATIONS
346	Magnitude of Impact of Executive Functioning and IQ on Episodic Memory in Schizophrenia. Biological Psychiatry, 2012, 71, 545-551.	0.7	23
347	Impaired Visual Cortical Plasticity in Schizophrenia. Biological Psychiatry, 2012, 71, 512-520.	0.7	118
348	The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in Spain. Schizophrenia Research, 2012, 134, 279-284.	1.1	62
349	Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophrenia Research, 2012, 135, 72-78.	1.1	72
350	Self-reported empathy deficits are uniquely associated with poor functioning in schizophrenia. Schizophrenia Research, 2012, 137, 196-202.	1.1	76
351	Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression. Schizophrenia Research, 2012, 138, 94-98.	1.1	20
352	Hippocampal novelty activations in schizophrenia: Disease and medication effects. Schizophrenia Research, 2012, 138, 157-163.	1.1	27
353	Longitudinal progression of frontal and temporal lobe changes in schizophrenia. Schizophrenia Research, 2012, 139, 1-6.	1.1	75
354	Cholinergic pathways and cognition in patients with schizophrenia: A pilot study. Schizophrenia Research, 2012, 139, 46-52.	1.1	8
355	Metabotropic Glutamate Receptors for New Treatments in Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 297-365.	0.9	33
356	Cognitive Impairment in Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 11-37.	0.9	335
357	The Role of Dopamine D3 Receptors in Antipsychotic Activity and Cognitive Functions. Handbook of Experimental Pharmacology, 2012, , 167-210.	0.9	90
358	L'évaluation des fonctions neurocognitives dans la schizophrénieÂ: de l'examen complémentaire Â fonction thérapeutique. Journal De Thérapie Comportementale Et Cognitive, 2012, 22, 117-124.	А́ la 0.2	0
359	De l'importance du bilan neuropsychologique avant la TCC pour les patients souffrant de schizophrénie. Journal De Thérapie Comportementale Et Cognitive, 2012, 22, 111-116.	0.2	0
360	A human computer interface drived rehabilitation system for upper limb motion recovery. , 2012, , .		0
361	Schizotypy and genetic loading for schizophrenia impact upon neuropsychological status in bipolar II and unipolar major depressive disorders. Journal of Affective Disorders, 2012, 142, 225-232.	2.0	23
362	The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry, 2012, 12, 172.	1.1	161
363	Neurofeedback for the treatment of schizophrenia: Case study. , 2012, , .		5

#	Article	IF	CITATIONS
364	Attentional Processing in C57BL/6J Mice Exposed to Developmental Vitamin D Deficiency. PLoS ONE, 2012, 7, e35896.	1.1	31
365	Cognitive Remediation in Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2012, 10, 125-135.	0.9	39
366	Psychomotor Performance Relevant to Driving Ability in Patients with Schizophrenia Treated with Haloperidol and Aripiprazole. Korean Journal of Schizophrenia Research, 2012, 15, 99.	0.3	0
367	Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology, 2012, 220, 627-637.	1.5	127
368	Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia. Neuropsychopharmacology, 2012, 37, 16-42.	2.8	177
369	Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene–environment interaction: objectives, sample characteristics, recruitment and assessment methods. International Journal of Methods in Psychiatric Research, 2012, 21, 205-221.	1.1	224
370	Cognitive Deficits in Schizophrenia. Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1, 45-52.	0.7	5
371	A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. European Journal of Pharmacology, 2012, 685, 59-69.	1.7	57
372	Transcranial magnetic stimulation on the modulation of gamma oscillations in schizophrenia. Annals of the New York Academy of Sciences, 2012, 1265, 25-35.	1.8	41
373	Do the same factors predict outcome in schizophrenia and non-schizophrenia syndromes after first-episode psychosis? A two-year follow-up study. Journal of Psychiatric Research, 2012, 46, 774-781.	1.5	25
374	Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews, 2012, 36, 1188-1216.	2.9	56
375	Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology, 2013, 226, 91-100.	1.5	76
376	Functional dysconnectivity in schizophrenia and its relationship to neural synchrony. Expert Review of Neurotherapeutics, 2013, 13, 755-765.	1.4	18
377	Specific vs general cognitive remediation for executive functioning in schizophrenia: A multicenter randomized trial. Schizophrenia Research, 2013, 147, 68-74.	1.1	72
378	Predictors of performance improvements within a cognitive remediation program for schizophrenia. Psychiatry Research, 2013, 209, 375-380.	1.7	18
379	Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: A meta-analysis. Schizophrenia Research, 2013, 149, 48-55.	1.1	97
380	Integrated Psychological Therapy: Effectiveness in Schizophrenia Inpatient Settings Related to Patients' Age. American Journal of Geriatric Psychiatry, 2013, 21, 231-241.	0.6	27
381	The interaction of affective with psychotic processes: A test of the effects of worrying on working memory, jumping to conclusions, and anomalies of experience in patients with persecutory delusions. Journal of Psychiatric Research, 2013, 47, 1837-1842.	1.5	43

#	Article	IF	CITATIONS
382	Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative. Neuroscience and Biobehavioral Reviews, 2013, 37, 2166-2180.	2.9	104
383	The <i>KCNH2</i> gene is associated with neurocognition and the risk of schizophrenia. World Journal of Biological Psychiatry, 2013, 14, 114-120.	1.3	36
384	WAIS-IV Profile of Cognition in Schizophrenia. Assessment, 2013, 20, 462-473.	1.9	32
385	At Risk for Schizophrenic or Affective Psychoses? A Meta-Analysis of DSM/ICD Diagnostic Outcomes in Individuals at High Clinical Risk. Schizophrenia Bulletin, 2013, 39, 923-932.	2.3	165
386	Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 155-166.	1.4	76
387	Neurocognition and symptoms identify links between facial recognition and emotion processing in schizophrenia: Meta-analytic findings. Schizophrenia Research, 2013, 151, 78-84.	1.1	89
388	Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. Neuroscience, 2013, 255, 55-67.	1.1	20
389	Correlations between executive function, decision-making and impulsivity are disrupted in schizophrenia versus controls. Psychiatry Research, 2013, 205, 168-171.	1.7	8
390	The influence of impaired processing speed on cognition in first-episode antipsychotic-naÃ <sup>-</sup> ve schizophrenic patients. European Psychiatry, 2013, 28, 332-339.	0.1	38
391	The association of cardiac vagal control and executive functioning – Findings from the MIDUS study. Journal of Psychiatric Research, 2013, 47, 628-635.	1.5	62
392	Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia. Schizophrenia Research, 2013, 146, 238-243.	1.1	25
393	Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research, 2013, 146, 217-223.	1.1	14
394	Polymorphisms in schizophrenia candidate gene UFD1L may contribute to cognitive deficits. Psychiatry Research, 2013, 209, 110-113.	1.7	5
395	Effects of lurasidone on executive function in common marmosets. Behavioural Brain Research, 2013, 246, 125-131.	1.2	21
396	Impairments in set-shifting but not reversal learning in the neonatal ventral hippocampal lesion model of schizophrenia: Further evidence for medial prefrontal deficits. Behavioural Brain Research, 2013, 256, 405-413.	1.2	21
397	Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophrenia Research, 2013, 146, 224-230.	1.1	43
398	End-of-Life (Care) Perspectives and Expectations of Patients With Schizophrenia. Archives of Psychiatric Nursing, 2013, 27, 246-252.	0.7	20
399	Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms. Schizophrenia Research, 2013, 147, 223-229.	1.1	30

ARTICLE IF CITATIONS Self-efficacy and functional status in schizophrenia: Relationship to insight, cognition and negative 400 1.1 40 symptoms. Schizophrenia Research, 2013, 145, 69-74. Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis. Schizophrenia Research, 2013, 146, 87-94. 1.1 Reduced white matter integrity and cognitive deficit in never-medicated chronic schizophrenia: A 402 1.2 88 diffusion tensor study using TBSS. Behavioural Brain Research, 2013, 252, 157-163. Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: Evidence 1.1 from a translational Sustained Áttention Task. Schizophrenia Research, 2013, 144, 136-141. Generalization of cognitive training in an Australian sample of schizophrenia patients. Comprehensive 404 1.5 3 Psychiatry, 2013, 54, 865-872. Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia. Schizophrenia Research, 2013, 143, 125-131. 1.1 Persistence, diagnostic specificity and genetic liability for context-processing deficits in 406 1.1 18 schizophrenia. Schizophrenia Research, 2013, 147, 75-80. Muscarinic M1 receptor agonists: can they improve cognitive performance?. International Journal of Neuropsychopharmacology, 2013, 16, 717-720. 1.0 10 Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental 408 schizophrenic model in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 2.5 45 45, 107-116. Confirmatory factor analysis reveals a latent cognitive structure common to bipolar disorder, 409 1.1 39 schizophrenia, and normal controls. Bipolar Disorders, 2013, 15, 422-433. Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology, 2013, 64, 410 2.0 57 294-304. Egis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology, 2013, 64, 254-263. Does practice make perfect? Results from a Chinese feasibility study of cognitive remediation in 412 1.0 6 schizophrenia. Neuropsychological Rehabilitation, 2013, 23, 580-596. Cognitive remediation as a treatment for major depression: A rationale, review of evidence and recommendations for future research. Australian and New Zealand Journal of Psychiatry, 2013, 47, 1.3 74 1165-1175. A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia. CPT: 20 414 1.3 Pharmacometrics and Systems Pharmacology, 2013, 2, 1-8. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of 79 efficacy. British Journal of Psychiatry, 2013, 203, 172-178. Defective Processing Speed and Nonclinical Psychotic Experiences in Children: Longitudinal Analyses 416 4.0 43 in a Large Birth Cohort. American Journal of Psychiatry, 2013, 170, 550-557. A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive 2.8 170

Enhancement in Schizophrenia. Neuropsychopharmacology, 2013, 38, 968-975.

CITATION REPORT

#

ARTICLE IF CITATIONS Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese 0.3 14 418 Sample. Archives of Clinical Neuropsychology, 2013, 28, 845-858. Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So 2.3 Far?. Schizophrenia Bulletin, 2013, 39, 417-435. Symptom Domains and Neurocognitive Functioning Can Help Differentiate Social Cognitive Processes 420 2.3 187 in Schizophrenia: A Meta-Analysis. Schizophrenia Bulletin, 2013, 39, 102-111. Factor Structure of Social Cognition in Schizophrenia: Is Empathy Preserved?. Schizophrenia Research 421 and Treatment, 2013, 2013, 1-13. Cognitive Remediation in Schizophrenia: Current Status and Future Perspectives. Schizophrenia 422 0.7 82 Research and Treatment, 2013, 2013, 1-12. The Neural Correlates of Mental Rotation Abilities in Cannabis-Abusing Patients with Schizophrenia: An fMRI Study. Schizophrenia Research and Treatment, 2013, 2013, I-10. A comparison of cognitive functioning in acute schizophrenia and depression. Acta 424 1.0 7 Neuropsychiatrica, 2013, 25, 334-341. Differences in onset of disease and severity of psychopathology between toxoplasmosisâ€related and 58 toxoplasmosisâ€unrelated schizophrenia. Ácta Psychiatrica Scandinavica, 2013, 127, 227-238. Profile of cognitive deficits and associations with depressive symptoms and intelligence in chronic 426 0.8 4 earlyâ€onset schizophrenia patients. Scandinavian Journal of Psychology, 2013, 54, 363-370. Dichotic listening, executive functions and grey matter cortical volume in patients with 0.8 schizophrenia and healthy controls. Scandinavian Journal of Psychology, 2013, 54, 443-450. Factor Structure of Neurocognition and Functional Capacity in Schizophrenia: A Multidimensional Examination of Temporal Stability. Journal of the International Neuropsychological Society, 2013, 19, 428 1.2 25 656-663. Differentiation between deviant trajectory planning, action planning, and reduced psychomotor speed in schizophrenia. Cognitive Neuropsychiatry, 2013, 18, 284-303. Estudos traducionais de neuropsiguiatria e esquizofrenia: modelos animais genéticos e de 430 0.6 5 neurodesenvolvimento. Revista De Psiquiatria Clinica, 2013, 40, 41-50. Cognition as a central illness feature in schizophrenia., 0, , 1-23. 432 Assessment of cognition in schizophrenia treatment studies., 0,, 231-246. 0 Fragmented Perception: Slower Space-Based but Faster Object-Based Attention in Recent-Onset Psychosis with and without Schizophrenia. PLoS ONE, 2013, 8, e59983. Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the 434 1.335 Evidence?. Frontiers in Psychiatry, 2013, 4, 157. Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation. Frontiers in Behavioral Neuroscience, 2013, 7, 180.

ARTICLE IF CITATIONS # Attention and multisensory integration of emotions in schizophrenia. Frontiers in Human 436 1.0 17 Neuroscience, 2013, 7, 674. Northwestern University Schizophrenia Data and Software Tool (NUSDAST). Frontiers in 1.3 Neuroinformatics, 2013, 7, 25. Participants With Schizophrenia Retain the Information Necessary for Informed Consent During 438 1.1 8 Clinical Trials. Journal of Clinical Psychiatry, 2013, 74, 622-627. The multi-faceted, "global―cognitive impairment profile in schizophrenia. , 2013, , 24-49. Computerized cognitive training in schizophrenia: current knowledge and future directions., 0,, 440 2 284-315. Correlation of Lifetime Symptom Dimensions with Cognitive Function and Other Clinical Characteristics in Schizophrenia Patients. Korean Journal of Schizophrenia Research, 2014, 17, 72. 0.3 A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and 442 1.3 35 Inflammation. Frontiers in Psychiatry, 2014, 5, 11. An investigation of reasoning by analogy in schizophrenia and autism spectrum disorder. Frontiers in 1.0 16 Human Neuroscience, 2014, 8, 517. Neurocognition, social cognition and functional outcome in schizophrenia. European Journal of 444 0.7 10 Psychiatry, 2014, 28, 201-211. Positive and negative subclinical symptoms and MCCB performance in non-psychiatric controls. 445 Schizophrenia Research: Cognition, 2014, 1, 175-179. Targeting Kynurenine Aminotransferase II in Psychiatric Diseases: Promising Effects of an Orally Active 446 2.363 Enzyme Inhíbitor. Schizophrenia Bulletin, 2014, 40, S152-S158. Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches. American Journal of Psychiatric Rehabilitation, 2014, 17, 225-253. Changes in aspects of cognitive functioning in young patients with schizophrenia during group psychodynamic psychotherapy: A preliminary study. Nordic Journal of Psychiatry, 2014, 68, 333-340. 448 0.7 5 Association between schizophrenia symptoms and neurocognition on mobility in older adults with schizophrenia. Aging and Mental Health, 2014, 18, 1006-1012. 449 1.5 Cognitive subtypes in non-affected siblings of schizophrenia patients: characteristics and profile 450 2.7 16 congruency with affected family members. Psychological Medicine, 2014, 44, 395-405. Refining the latent structure of neuropsychological performance in schizophrenia. Psychological Medicine, 2014, 44, 3557-3570. Working Memory Training in Schizophrenia and Healthy Populations. Behavioral Sciences (Basel,) Tj ETQq0 0 0 rgBT (Overlock, 10 Tf 50 452

<sup>453</sup>Cognitive Mapping Deficits in Schizophrenia: A Critical Overview. Indian Journal of Psychological<br/>Medicine, 2014, 36, 9-26.0.66

#	Article	IF	CITATIONS
454	Psychosocial support and cognitive deficits in adults with schizophrenia. International Journal of Social Psychiatry, 2014, 60, 417-425.	1.6	4
455	Motivational Salience Signal in the Basal Forebrain Is Coupled with Faster and More Precise Decision Speed. PLoS Biology, 2014, 12, e1001811.	2.6	38
456	The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Frontiers in Psychiatry, 2014, 5, 159.	1.3	30
457	Brief report: The impact of alcohol and cannabis misuse on cognition among individuals with schizophrenia. Schizophrenia Research: Cognition, 2014, 1, 160-163.	0.7	2
458	Comparison of self-report and performance-based measures of everyday functioning in individuals with schizophrenia: implications for measure selection. Cognitive Neuropsychiatry, 2014, 19, 485-494.	0.7	15
459	Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study. Human Psychopharmacology, 2014, 29, 446-458.	0.7	26
460	Re-evaluating the PCP challenge as a pre-clinical model of impaired cognitive flexibility in schizophrenia. European Neuropsychopharmacology, 2014, 24, 1836-1849.	0.3	24
461	Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning. Psychiatry Research, 2014, 220, 784-791.	1.7	80
462	Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness. Acta Psychiatrica Scandinavica, 2014, 129, 126-133.	2.2	23
463	Validation of the <scp>P</scp> ersian version of the Brief Assessment of Cognition in Schizophrenia in patients with schizophrenia and healthy controls. Psychiatry and Clinical Neurosciences, 2014, 68, 160-166.	1.0	17
464	Enhanced Neurocognitive Functioning and Positive Temperament in Twins Discordant for Bipolar Disorder. American Journal of Psychiatry, 2014, 171, 1191-1198.	4.0	29
465	The MATRICS Consensus Cognitive Battery: What We Know 6 Years Later. American Journal of Psychiatry, 2014, 171, 1151-1154.	4.0	41
466	Performance on the <scp>W</scp> echsler <scp>A</scp> dult <scp>I</scp> ntelligence <scp>S</scp> caleâ€ <scp>III</scp> in <scp>J</scp> apanese patients with schizophrenia. Psychiatry and Clinical Neurosciences, 2014, 68, 534-541.	1.0	38
467	Abnormalities of mental rotation of hands associated with speed of information processing and executive function in chronic schizophrenic patients. Psychiatry and Clinical Neurosciences, 2014, 68, 410-417.	1.0	8
468	Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. Biomarkers in Medicine, 2014, 8, 29-49.	0.6	13
469	Associations of Schizophrenia Symptoms and Neurocognition With Physical Activity in Older Adults With Schizophrenia. Biological Research for Nursing, 2014, 16, 23-30.	1.0	39
470	Executive functioning and psychopathological profile in relatives of individuals with deficit <i>v.</i> non-deficit schizophrenia: a pilot study. Epidemiology and Psychiatric Sciences, 2014, 23, 85-97.	1.8	10
471	Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectrums, 2014, 19, 35-53.	0.7	132

# 472	ARTICLE Protocol to evaluate the impact of yoga supplementation on cognitive function in schizophrenia: a randomised controlled trial. Acta Neuropsychiatrica, 2014, 26, 280-290.	IF 1.0	CITATIONS
473	Understanding jumping to conclusions in patients with persecutory delusions: working memory and intolerance of uncertainty. Psychological Medicine, 2014, 44, 3017-3024.	2.7	54
474	Cognitive remediation in schizophrenia: background, techniques, evidence of efficacy and perspectives. Epidemiology and Psychiatric Sciences, 2014, 23, 21-25.	1.8	18
475	Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders. , 2014, 143, 253-264.		28
476	Resting-State fMRI Connectivity Impairment in Schizophrenia and Bipolar Disorder. Schizophrenia Bulletin, 2014, 40, 100-110.	2.3	125
477	Psychopharmacological Treatment of Neurocognitive Deficits in People with Schizophrenia: A Review of Old and New Targets. CNS Drugs, 2014, 28, 301-318.	2.7	16
478	Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. Psychopharmacology, 2014, 231, 765-775.	1.5	23
479	Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 333-343.	1.8	50
480	Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cognitive, Affective and Behavioral Neuroscience, 2014, 14, 388-406.	1.0	66
481	12â€month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disorders, 2014, 16, 159-171.	1.1	49
482	The Relationship of Attitudinal Beliefs to Negative Symptoms, Neurocognition, and Daily Functioning in Recent-Onset Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1308-1318.	2.3	60
483	The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: Barking up the wrong tree?. Psychopharmacology, 2014, 231, 543-550.	1.5	20
484	Cannabis-Related Working Memory Deficits and Associated Subcortical Morphological Differences in Healthy Individuals and Schizophrenia Subjects. Schizophrenia Bulletin, 2014, 40, 287-299.	2.3	63
485	Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. International Journal of Neuropsychopharmacology, 2014, 17, 961-977.	1.0	119
486	Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approach. Psychoneuroendocrinology, 2014, 50, 95-105.	1.3	22
487	Neurocognition in schizophrenia: From prodrome to multi-episode illness. Psychiatry Research, 2014, 220, 129-134.	1.7	56
488	Neurocognitive Pattern Analysis Reveals Classificatory Hierarchy of Attention Deficits in Schizophrenia. Schizophrenia Bulletin, 2014, 40, 878-885.	2.3	16
489	Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100. Neuropsychopharmacology, 2014, 39, 1578-1593.	2.8	91

#	Article	IF	CITATIONS
490	Developing Visually Based, Low-Literacy Health Education Tools for African Americans with Psychotic Disorders and Their Families. Community Mental Health Journal, 2014, 50, 629-636.	1.1	10
491	Tetrahydronaphthyridine and Dihydronaphthyridinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu <sub>5</sub> ). Journal of Medicinal Chemistry, 2014, 57, 5620-5637.	2.9	13
492	Poster #S133 ASSOCIATION OF A RISK ALLELE OF ANK3 WITH COGNITIVE PERFORMANCE AND CORTICAL THICKNESS IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS. Schizophrenia Research, 2014, 153, S136-S137.	1.1	0
493	TCF4 gene polymorphism and cognitive performance in patients with first episode psychosis. Schizophrenia Research, 2014, 152, 124-129.	1.1	30
494	Cognitive task performance and symptoms contribute to personality abnormalities in first hospitalized schizophrenia. Journal of Psychiatric Research, 2014, 55, 68-76.	1.5	15
495	Changes in memory performance over a 12-month period in relation to achieving symptomatic remission after a first-episode psychosis. Schizophrenia Research, 2014, 153, 103-108.	1.1	15
496	Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Cellular Signalling, 2014, 26, 2284-2297.	1.7	40
497	The effects of acute and repeated administration of ketamine on attentional performance in the five-choice serial reaction time task in rats. European Neuropsychopharmacology, 2014, 24, 1381-1393.	0.3	32
498	No sex differences in neuropsychological performance in first episode psychosis patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 149-154.	2.5	47
499	The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Reviews in the Neurosciences, 2014, 25, 367-82.	1.4	29
500	A fiveâ€year followâ€up study of neurocognitive functioning in bipolar disorder. Bipolar Disorders, 2014, 16, 722-731.	1.1	76
501	Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia. Neuroscience Letters, 2014, 575, 37-41.	1.0	27
502	Predictors of cognition in first episode psychosis. Schizophrenia Research, 2014, 152, 164-169.	1.1	14
503	La conscience des déficits neurocognitifs dans la schizophrénieÂ: une méta-analyse. Sante Mentale Au Quebec, 0, 39, 183-200.	0.1	15
504	Neurocognition: Clinical and Functional Outcomes in Schizophrenia. Canadian Journal of Psychiatry, 2014, 59, 5-12.	0.9	199
505	Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychological Medicine, 2015, 45, 2657-2666.	2.7	37
506	Patterns of Emotion Attribution are Affected in Patients with Schizophrenia. Spanish Journal of Psychology, 2015, 18, E59.	1.1	5
507	Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients. Journal of the International Neuropsychological Society, 2015, 21, 868-879.	1.2	27

#	Article	IF	CITATIONS
508	Cognitive deficits characterization using the CogState Research Battery in first-episode psychosis patients. Schizophrenia Research: Cognition, 2015, 2, 140-145.	0.7	18
509	Addressing Cognitive Challenges in Schizophrenia: A Public Health Perspective. Journal of Psychosocial Rehabilitation and Mental Health, 2015, 2, 103-105.	0.4	0
510	Neurocognitive predictors of performanceâ€based functional capacity in bipolar disorder. Journal of Neuropsychology, 2015, 9, 159-171.	0.6	17
511	MK-801-induced deficits in social recognition in rats. Behavioural Pharmacology, 2015, 26, 748-765.	0.8	35
512	Effects of genetic variations in NRG1 on cognitive domains in patients with schizophrenia and healthy individuals. Psychiatric Genetics, 2015, 25, 147-154.	0.6	12
513	Investigation of cognition in schizophrenia: psychometric properties of instruments for assessing working memory updating. Jornal Brasileiro De Psiquiatria, 2015, 64, 238-246.	0.2	3
514	Neuronal migration abnormalities and its possible implications for schizophrenia. Frontiers in Neuroscience, 2015, 9, 74.	1.4	68
515	Associations Between Components of Metabolic Syndrome and Cognition in Patients With Schizophrenia. Journal of Psychiatric Practice, 2015, 21, 190-197.	0.3	29
516	INT-Integrated Neurocognitive Therapy for Schizophrenia Patients. , 2015, , .		4
517	Animal Paradigms to Assess Cognition with Translation to Humans. Handbook of Experimental Pharmacology, 2015, 228, 27-57.	0.9	21
518	Prefrontal Cortical GABA Modulation of Spatial Reference and Working Memory. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	41
519	Subjective perceptions of cognitive deficits and their influences on quality of life among patients with schizophrenia. Quality of Life Research, 2015, 24, 2753-2760.	1.5	12
520	The muscarinic system, cognition and schizophrenia. Neuroscience and Biobehavioral Reviews, 2015, 55, 393-402.	2.9	81
521	Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research, 2015, 163, 38-46.	1.1	62
522	Impaired Limbic Cortico-Striatal Structure and Sustained Visual Attention in a Rodent Model of Schizophrenia. International Journal of Neuropsychopharmacology, 2015, 18, pyu010-pyu010.	1.0	28
523	Understanding Symbol Coding in Schizophrenia. Biological Psychiatry, 2015, 78, 744-746.	0.7	5
525	Cascading and combined effects of cognitive deficits and residual symptoms on functional outcome in schizophrenia – A path-analytical approach. Psychiatry Research, 2015, 229, 264-271.	1.7	32
526	Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bulletin, 2015, 42, sbv111.	2.3	34

#	Article	IF	CITATIONS
527	Persistence of effectiveness of cognitive remediation interventions in schizophrenia: A 1-year follow-up study. Schizophrenia Research, 2015, 161, 403-406.	1.1	21
528	F-18 fluorodeoxyglucose positron emission tomography study of impaired emotion processing in first episode schizophrenia. Schizophrenia Research, 2015, 162, 103-107.	1.1	10
529	S-SCAM, A Rare Copy Number Variation Gene, Induces Schizophrenia-Related Endophenotypes in Transgenic Mouse Model. Journal of Neuroscience, 2015, 35, 1892-1904.	1.7	19
530	Brain Rhythms Connect Impaired Inhibition to Altered Cognition in Schizophrenia. Biological Psychiatry, 2015, 77, 1020-1030.	0.7	74
531	Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophrenia Research, 2015, 163, 73-79.	1.1	52
532	A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology, 2015, 40, 2025-2037.	2.8	258
533	Alterations in spatial memory and anxiety in the MAM E17 rat model of hippocampal pathology in schizophrenia. Psychopharmacology, 2015, 232, 4099-4112.	1.5	22
534	Meta-analysis of Cognitive Impairment in First-Episode Bipolar Disorder: Comparison With First-Episode Schizophrenia and Healthy Controls. Schizophrenia Bulletin, 2015, 41, 1095-1104.	2.3	250
535	Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) Study: The moderating role of smoking status and antipsychotic medications. Schizophrenia Research, 2015, 163, 24-31.	1.1	26
536	Neuroanatomical Mechanism on the Effect of Distraction in Working Memory Maintenance in Patients With Schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, e1-e9.	0.9	22
537	Observable Social Cognition – A Rating Scale: an interview-based assessment for schizophrenia. Cognitive Neuropsychiatry, 2015, 20, 198-221.	0.7	40
538	Working memory training triggers delayed chromatin remodeling in the mouse corticostriatothalamic circuit. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 60, 93-103.	2.5	7
539	Theory of mind in the early course of schizophrenia: stability, symptom and neurocognitive correlates, and relationship with functioning. Psychological Medicine, 2015, 45, 2031-2043.	2.7	65
540	Prefrontal Cortical Gamma-Aminobutyric Acid Transmission and Cognitive Function: Drawing Links to Schizophrenia from Preclinical Research. Biological Psychiatry, 2015, 77, 929-939.	0.7	56
541	Recovery and reliable change rates for patients scoring severe on depression, anxiety or impaired functioning in a psychological therapies service: IAPT. Mental Health Review Journal, 2015, 20, 28-35.	0.3	27
542	The Puzzle of Processing Speed, Memory, and Executive Function Impairments in Schizophrenia: Fitting the Pieces Together. Biological Psychiatry, 2015, 78, 786-793.	0.7	63
543	The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats. Pharmacological Reports, 2015, 67, 1183-1187.	1.5	17
544	The Experience of Cognitive Impairment in People with Psychosis. Clinical Psychology and Psychotherapy, 2015, 22, 193-207.	1.4	8

#	Article	IF	Citations
545	Preserved Learning during the Symbolââ,¬â€œDigit Substitution Test in Patients with Schizophrenia, Age-Matched Controls, and Elderly. Frontiers in Psychiatry, 2014, 5, 189.	1.3	18
546	Auditory Cortical Plasticity Drives Training-Induced Cognitive Changes in Schizophrenia. Schizophrenia Bulletin, 2015, 42, sbv087.	2.3	58
547	The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacology, 2015, 232, 4059-4083.	1.5	36
548	The impact of motivation on cognitive performance in an animal model of the negative and cognitive symptoms of schizophrenia Behavioral Neuroscience, 2015, 129, 292-299.	0.6	19
549	Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia. Psychoneuroendocrinology, 2015, 57, 125-133.	1.3	6
550	Modeling the Neuroanatomical and Neurocognitive Mechanisms of Cognitive Insight in Non-clinical Subjects. Cognitive Therapy and Research, 2015, 39, 415-423.	1.2	8
551	One-Year Randomized Controlled Trial and Follow-Up of Integrated Neurocognitive Therapy for Schizophrenia Outpatients. Schizophrenia Bulletin, 2015, 41, 604-616.	2.3	81
552	Methods for Delivering and Evaluating the Efficacy of Cognitive Enhancement. Handbook of Experimental Pharmacology, 2015, 228, 5-25.	0.9	3
553	Facial affect processing deficits in schizophrenia: A meta-analysis of antipsychotic treatment effects. Journal of Psychopharmacology, 2015, 29, 224-229.	2.0	24
554	The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial. Schizophrenia Bulletin, 2015, 41, 859-868.	2.3	164
555	Role for the M <sub>1</sub> Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. ACS Chemical Neuroscience, 2015, 6, 1683-1695.	1.7	48
556	Effects of D- and L-govadine on the disruption of touchscreen object-location paired associates learning in rats by acute MK-801 treatment. Psychopharmacology, 2015, 232, 4371-4382.	1.5	18
557	Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments. Progress in Neurobiology, 2015, 134, 178-201.	2.8	71
558	Intermethod reliability and factors affecting recall with the Temple University Community Participation measure. Journal of Mental Health, 2015, 24, 189-195.	1.0	21
559	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2015, 41, 1237-1247.	2.3	45
560	The MCCB impairment profile in a Spanish sample of patients with schizophrenia: Effects of diagnosis, age, and gender on cognitive functioning. Schizophrenia Research, 2015, 169, 116-120.	1.1	16
561	Cognitive structure from childhood to adulthood in kindreds densely affected by schizophrenia and bipolar disorder. Psychiatry Research, 2015, 229, 101-108.	1.7	1
562	Brain structure and function correlates of cognitive subtypes in schizophrenia. Psychiatry Research - Neuroimaging, 2015, 234, 74-83.	0.9	64

#	Article	IF	CITATIONS
563	Are negative symptoms really related to cognition in schizophrenia?. Psychiatry Research, 2015, 230, 377-382.	1.7	19
564	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. Schizophrenia Research, 2015, 166, 304-309.	1.1	26
565	Randomized controlled trial of computer-based treatment of social cognition in schizophrenia: the TRuSST trial protocol. BMC Psychiatry, 2015, 15, 142.	1.1	26
566	Neurocognitive similarities between severe chronic schizophrenia and behavioural variant frontotemporal dementia. Psychiatry Research, 2015, 225, 658-666.	1.7	12
567	α4β2 nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: Implications for cognitive dysfunction in schizophrenia. Neuropharmacology, 2015, 90, 42-52.	2.0	20
568	10 year course of IQ in first-episode psychosis: Relationship between duration of psychosis and long-term intellectual trajectories. Psychiatry Research, 2015, 225, 515-521.	1.7	19
569	Oxytocin and social cognition in affective and psychotic disorders. European Neuropsychopharmacology, 2015, 25, 265-282.	0.3	34
570	Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 147-154.	1.8	12
571	The course of neuropsychological impairment and brain structure abnormalities in psychotic disorders. Neuroscience Research, 2016, 102, 39-46.	1.0	20
572	Astrocytes as Pharmacological Targets in the Treatment of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 423-443.	0.7	17
573	Glutamate Pharmacological Models Relevant to Schizophrenia and Psychosis. Handbook of Behavioral Neuroscience, 2016, , 139-174.	0.7	3
574	Faux Pas Test in schizophrenic patients. Jornal Brasileiro De Psiquiatria, 2016, 65, 17-21.	0.2	9
575	Oligodendrocyte and Interneuron Density in Hippocampal Subfields in Schizophrenia and Association of Oligodendrocyte Number with Cognitive Deficits. Frontiers in Cellular Neuroscience, 2016, 10, 78.	1.8	37
576	Evidence for Trait Related Theory of Mind Impairment in First Episode Psychosis Patients and Its Relationship with Processing Speed: A 3 Year Follow-up Study. Frontiers in Psychology, 2016, 7, 592.	1.1	21
578	Revisiting the validity of measures of social cognitive bias in schizophrenia: Additional results from the Social Cognition Psychometric Evaluation (SCOPE) study. British Journal of Clinical Psychology, 2016, 55, 441-454.	1.7	39
579	Cognitive functioning and employment among people with schizophrenia in vocational rehabilitation. Work, 2016, 54, 735-744.	0.6	11
580	The prevalence of visual hallucinations in non-affective psychosis, and the role of perception and attention. Psychological Medicine, 2016, 46, 1735-1747.	2.7	16
581	Event-related potentials demonstrate deficits in acoustic segmentation in schizophrenia. Schizophrenia Research, 2016, 173, 109-115.	1.1	9

#	Article	IF	CITATIONS
582	Spectral EEG abnormalities during vibrotactile encoding and quantitative working memory processing in schizophrenia. NeuroImage: Clinical, 2016, 11, 578-587.	1.4	8
583	Meta-analysis of Theory of Mind (ToM) impairment in bipolar disorder. Psychological Medicine, 2016, 46, 253-264.	2.7	164
584	Social cognition in schizophrenia in comparison to bipolar disorder: A meta-analysis. Schizophrenia Research, 2016, 175, 72-78.	1.1	124
585	Executive dysfunction and cognitive subgroups in a large sample of euthymic patients with bipolar disorder. European Neuropsychopharmacology, 2016, 26, 1338-1347.	0.3	91
586	Relationship Between Objectively Measured Sedentary Behavior and Cognitive Performance in Patients With Schizophrenia Vs Controls. Schizophrenia Bulletin, 2017, 43, sbw126.	2.3	30
587	The effects of cigarette smoking behavior and psychosis history on general and social cognition in bipolar disorder. Bipolar Disorders, 2016, 18, 528-538.	1.1	8
588	Theory of Mind as a mediator variable between neurocognition and functioning in young individuals in treatment with secondary services for non-psychotic disorders. Psychiatry Research, 2016, 246, 415-420.	1.7	6
589	Molecular signatures associated with cognitive deficits in schizophrenia: a study of biopsied olfactory neural epithelium. Translational Psychiatry, 2016, 6, e915-e915.	2.4	30
590	Repetitive Noninvasive Brain Stimulation to Modulate Cognitive Functions in Schizophrenia: A Systematic Review of Primary and Secondary Outcomes. Schizophrenia Bulletin, 2016, 42, S95-S109.	2.3	49
591	The relationship between change in cognition and change in functional ability in schizophrenia during cognitive and psychosocial rehabilitation. Psychiatry Research, 2016, 244, 145-150.	1.7	26
592	Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin's Former Hospital. Schizophrenia Bulletin, 2016, 42, S81-S89.	2.3	7
593	White matter correlates of episodic memory encoding and retrieval in schizophrenia. Psychiatry Research - Neuroimaging, 2016, 254, 188-198.	0.9	11
594	Working memory genetics in schizophrenia and related disorders: An RDoC perspective. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 121-131.	1.1	36
595	Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2017, 43, sbw115.	2.3	270
596	Validation of the cognitively normal range and below normal range subtypes in chronically hospitalized patients with schizophrenia. Schizophrenia Research: Cognition, 2016, 5, 28-34.	0.7	4
597	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. Psychological Medicine, 2016, 46, 2133-2144.	2.7	36
598	The effect of an acute bout of exercise on executive function among individuals with schizophrenia. Psychiatry Research, 2016, 246, 637-643.	1.7	8
599	Deficits in social cognition in first episode psychosis: A review of the literature. Clinical Psychology Review, 2016, 50, 108-137.	6.0	119

ARTICLE IF CITATIONS Increased plasma asymmetric dimethylarginine is associated with cognitive deficits in patients with 600 1.7 12 schizophrenia. Psychiatry Research, 2016, 246, 480-484. Mentalizing in schizophrenia: A multivariate functional MRI study. Neuropsychologia, 2016, 93, 158-166. 603 Neurocognitive findings in bipolar disorder: an update., 0, , 169-190. 0 Sensory Gating Deficits in First-Episode Psychosis. Journal of Nervous and Mental Disease, 2016, 204, 0.5 877-884. Social cognition in schizophrenia: Factor structure of emotion processing and theory of mind. 606 1.7 41 Psychiatry Research, 2016, 242, 150-156. Association between actigraphy-derived physical activity and cognitive performance in patients with schizophrenia. Psychological Medicine, 2016, 46, 2375-2384. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and 608 endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. World Journal of 1.330 Biological Psychiatry, 2016, 17, 406-428. Cognitive impairment and cortisol levels in first-episode schizophrenia patients. Stress, 2016, 19, 0.8 24 383-389. A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent 610 models for schizophrenia, implications for improved therapeutic strategies. Neuroscience and 2.9 59 Biobehavioral Reviews, 2016, 68, 979-1000. Abnormalities of cingulate cortex in antipsychotic-naÃ<sup>-</sup>ve chronic schizophrenia. Brain Research, 2016, 1.1 1638, 105-113. Efficacy and feasibility of the Integrated Psychological Therapy for outpatients with schizophrenia in 612 1.7 18 Greece: Final results of a RCT. Psychiatry Résearch, 2016, 242, 137-143. LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition 0.8 task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349. Cognitive Impairment in Schizophrenia: Interplay of BDNF and Childhood Trauma? A Review of 614 1.1 11 Literature. Psychiatric Quarterly, 2016, 87, 559-569. Evidence of Common Genetic Overlap Between Schizophrenia and Cognition. Schizophrenia Bulletin, 2.3 2016, 42, 832-842. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with 616 Schizophrenia in Rodent Models. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 1.3 41 587-595. Unitary construct of generalized cognitive ability underlying BACS performance across psychotic 1.1 disorders and in their first-degree relatives. Schizophrenia Research, 2016, 170, 156-161. Cognitive Assessment Interview (CAI): Validity as a co-primary measure of cognition across phases of 618 1.1 12 schizophrenia. Schizophrenia Research, 2016, 172, 137-142. Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental 1.1 data from two samples of volunteers. Schizophrenia Research, 2016, 172, 106-113.

ARTICLE IF CITATIONS Comparison of phencyclidine-induced spatial learning and memory deficits and reversal by sertindole 620 1.2 9 and risperidone between Lister Hooded and Wistar rats. Behavioural Brain Research, 2016, 305, 140-147. Social cognition in schizophrenia: factor structure, clinical and functional correlates. Journal of 1.0 Mental Health, 2016, 25, 330-337. Studies on the Effects Prenatal Immune Activation on Postnatal Behavior: Models of Developmental 622 0.2 0 Origins of Schizophrenia. Neuromethods, 2016, , 263-278. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. Neuropharmacology, 2016, 102, 244-253. Electrophysiological Correlates of Aberrant Motivated Attention and Salience Processing in 624 0.9 10 Unaffected Relatives of Schizophrenia Patients. Clinical EEG and Neuroscience, 2016, 47, 11-23. Cognitive Effects of High-Frequency rTMS in Schizophrenia Patients With Predominant Negative Symptoms: Results From a Multicenter Randomized Sham-Controlled Trial. Schizophrenia Bulletin, 2.3 2016, 42, 608-618. Comprehensive treatments for social cognitive deficits in schizophrenia: A critical review and 626 6.0 144 effect-size analysis of controlled studies. Clinical Psychology Review, 2016, 43, 80-89. Re-conceptualizing ASD Within a Dimensional Framework: Positive, Negative, and Cognitive Feature 1.7 Clusters. Journal of Autism and Developmental Disorders, 2016, 46, 342-351. Northwestern University schizophrenia data sharing for SchizConnect: A longitudinal dataset for 628 2.1 26 large-scale integration. NeuroImage, 2016, 124, 1196-1201. The effect of combined treatment with escitalopram and risperidone on the MK-801-induced changes in 629 1.5 14 the object recognition test in mice. Pharmacological Reports, 2016, 68, 116-120. Emotion and Theory of Mind in Schizophreniaâ€"Investigating the Role of the Cerebellum. Cerebellum, 630 1.4 81 2016, 15, 357-368. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of 2.3 Schizophrenia. Schizophrenia Bulletin, 2016, 42, 335-343. Psychosocial functioning in firstâ€episode psychosis and associations with neurocognition, social 632 0.9 46 cognition, psychotic and affective symptoms. Microbial Biotechnology, 2017, 11, 23-36. Evidence that communication impairment in schizophrenia is associated with generalized poor task 634 1.7 performance. Psychiatry Research, 2017, 249, 172-179. Validation of the tablet-administered Brief Assessment of Cognition (BAC App). Schizophrenia 635 1.1 62 Research, 2017, 181, 100-106. Prediction of functional outcome in young patients with a recent-onset psychiatric disorder: Beyond 1.1 the traditional diagnostic classification system. Schizophrenia Research, 2017, 185, 114-121. From neurological soft signs to functional outcome in young individuals in treatment with secondary services for non-psychotic disorders: a path analysis. Psychological Medicine, 2017, 47, 637 2.7 5 1192-1203. Cognitive Impairment in Euthymic Pediatric Bipolar Disorder: A Systematic Review and Meta-Analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 286-296.

#	Article	IF	CITATIONS
639	The relationship of cognitive improvement after cognitive remediation with social functioning in patients with schizophrenia and severe cognitive deficits. Schizophrenia Research, 2017, 185, 154-160.	1.1	15
640	Reality monitoring impairment in schizophrenia reflects specific prefrontal cortex dysfunction. NeuroImage: Clinical, 2017, 14, 260-268.	1.4	31
641	Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. Asian Journal of Psychiatry, 2017, 27, 12-15.	0.9	8
642	Does Integrated Neurocognitive Therapy (INT) reduce severe negative symptoms in schizophrenia outpatients?. Schizophrenia Research, 2017, 188, 92-97.	1.1	19
643	Classics in Chemical Neuroscience: Haloperidol. ACS Chemical Neuroscience, 2017, 8, 444-453.	1.7	48
644	The influence of the glutamatergic system on cognition in schizophrenia: A systematic review. Neuroscience and Biobehavioral Reviews, 2017, 77, 369-387.	2.9	40
645	The effect of active video games on cognitive functioning in clinical and non-clinical populations: A meta-analysis of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 2017, 78, 34-43.	2.9	273
646	Further evidence of alerted default network connectivity and association with theory of mind ability in schizophrenia. Schizophrenia Research, 2017, 184, 52-58.	1.1	26
647	Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version. Schizophrenia Research: Cognition, 2017, 7, 13-18.	0.7	24
648	Stereotype Knowledge and Endorsement in Schizophrenia. Psychopathology, 2017, 50, 342-346.	1.1	9
649	Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. Scientific Reports, 2017, 7, 11821.	1.6	47
650	Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. British Journal of Pharmacology, 2017, 174, 3173-3190.	2.7	17
651	The effect of the muscarinic M 1 receptor antagonist biperiden on cognition in medication free subjects with psychosis. European Neuropsychopharmacology, 2017, 27, 854-864.	0.3	15
652	Regulation of sustained attention, false alarm responding and implementation of conditional rules by prefrontal GABAA transmission: comparison with NMDA transmission. Psychopharmacology, 2017, 234, 2777-2792.	1.5	14
653	A one-week 5-choice serial reaction time task to measure impulsivity and attention in adult and adolescent mice. Scientific Reports, 2017, 7, 42519.	1.6	39
654	Sustaining attention to simple visual tasks: a central deficit in schizophrenia? A systematic review. Annals of the New York Academy of Sciences, 2017, 1408, 32-45.	1.8	21
655	A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans. European Neuropsychopharmacology, 2017, 27, 928-939.	0.3	17
656	Sustained attention ability in schizophrenia: Investigation of conflict monitoring mechanisms. Clinical Neurophysiology, 2017, 128, 1599-1607.	0.7	10

ARTICLE IF CITATIONS Smoking status and its relationship to demographic and clinical characteristics in first episode 657 1.5 19 psychosis. Journal of Psychiatric Research, 2017, 85, 83-90. Cognitive impairments in patients with first episode psychosis: The relationship between neurophysiological and neuropsychological assessments. Journal of Clinical Neuroscience, 2017, 36, 0.8 80-87. The course of cognitive functioning after first-episode of psychosis: A six month follow-up study. 659 1.1 4 Schizophrenia Research, 2017, 182, 31-41. Understanding Social Situations (USS): A proof-of-concept social–cognitive intervention targeting theory of mind and attributional bias in individuals with psychosis.. Psychiatric Rehabilitation Journal, 2017, 40, 12-20. Implications for the thalamic reticular nucleus in impaired attention and sleep in schizophrenia. 661 1.1 31 Schizophrenia Research, 2017, 180, 44-47. Dopamine D 1 signaling involvement in the effects of the phosphodiesterase 10A inhibitor, PDM-042 on cognitive function and extrapyramidal side effect in rats. Behavioural Brain Research, 2017, 317, 1.2 204-209. Recent Advances in Psychological Assessment and Test Construction., 2017, , 3-25. 663 2 Advances in Theoretical, Developmental, and Cross-Cultural Perspectives of Psychopathology. , 2017, , 664 293-342. Acute Kynurenine Challenge Disrupts Sleepâ€"Wake Architecture and Impairs Contextual Memory in 665 0.6 27 Adult Ráts. Sleep, 2017, 40, . Vom kognitiven Training zur Kognitiven Remediationstherapie: Nutzen und Grenzen. Verhaltenstherapie, 2017, 27, 170-179. Exercise Induced Neuroplasticity to Enhance Therapeutic Outcomes of Cognitive Remediation in Schizophrenia: Analyzing the Róle of Brai nderived Neurotrophic Factor. CNS and Neurological 667 0.8 24 Disorders - Drug Targets, 2017, 16, 638-651. The Importance of Metamemory Functioning to the Pathogenesis of Psychosis. Frontiers in 668 1.1 Psychology, 2017, 8, 304. Parameter-Based Evaluation of Attentional Impairments in Schizophrenia and Their Modulation by 669 1.3 9 Prefrontal Transcranial Direct Current Stimulation. Frontiers in Psychiatry, 2017, 8, 259. Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls. Revista Brasileira De Psiquiatria, 2017, 39, 302-308. 670 Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Frontiers in Behavioral 671 1.0 37 Neuroscience, 2017, 11, 106. Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?. Frontiers in 1.4 63 Neuroscience, 2017, 11, 155. 673 Cognitive Deficits in Schizophreniaa<sup>-†</sup>., 2017, , . 2 Use of the MATRICS consensus cognitive battery (MCCB) to evaluate cognitive deficits in bipolar 674 1.1 38 disorder: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0176212.

#	Article	IF	CITATIONS
675	Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study. Journal of Psychopharmacology, 2018, 32, 524-532.	2.0	31
676	Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. Pharmacological Reports, 2018, 70, 623-630.	1.5	9
677	Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Research, 2018, 263, 1-6.	1.7	55
678	Selective noradrenaline reuptake inhibitors for schizophrenia. The Cochrane Library, 2018, 2018, CD010219.	1.5	8
679	Group Activities to Promote Early Rehabilitation in an Acute Psychiatric Ward: A Relationship-Based Approach Focusing on Movies. International Journal of Group Psychotherapy, 2018, 68, 147-162.	0.4	2
680	Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. Journal of Psychiatric Research, 2018, 99, 50-61.	1.5	151
681	Premorbid IQ subgroups in first episode non affective psychosis patients: Long-term sex differences in function and neurocognition. Schizophrenia Research, 2018, 197, 370-377.	1.1	26
682	Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophrenia Research, 2018, 199, 395-402.	1.1	74
683	Test–Retest Reliability and Minimal Detectable Change of the D2 Test of Attention in Patients with Schizophrenia. Archives of Clinical Neuropsychology, 2018, 33, 1060-1068.	0.3	16
684	Early cognitive basic symptoms are accompanied by neurocognitive impairment in patients with an â€~atâ€risk mental state' for psychosis. Microbial Biotechnology, 2018, 12, 586-595.	0.9	11
685	Impaired verbal learning in forensic inpatients with Schizophrenia Spectrum Disorder. Applied Neuropsychology Adult, 2018, 25, 189-196.	0.7	3
686	Occupational engagement and cognitive functioning among persons with schizophrenia: an explorative study. Scandinavian Journal of Occupational Therapy, 2018, 25, 172-179.	1.1	12
687	Psychosis and dementia: risk factor, prodrome, or cause?. International Psychogeriatrics, 2018, 30, 209-219.	0.6	49
688	Psychometrics of social cognitive measures for psychosis treatment research. Schizophrenia Research, 2018, 193, 51-57.	1.1	26
689	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology, 2018, 128, 492-502.	2.0	35
690	The association between cardio-respiratory fitness and cognition in schizophrenia. Schizophrenia Research, 2018, 193, 418-422.	1.1	11
691	Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. Psychiatry Research, 2018, 262, 542-548.	1.7	29
692	Motor abnormalities and cognitive impairment in first-episode psychosis patients, their unaffected siblings and healthy controls. Schizophrenia Research, 2018, 200, 50-55.	1.1	23

#	Article	IF	CITATIONS
693	Joint analysis of cognitive and circadian variation in Schizophrenia and Bipolar I Disorder. Asian Journal of Psychiatry, 2018, 38, 96-101.	0.9	7
694	NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology, 2018, 142, 41-62.	2.0	117
695	A Study on the Theory of Mind Deficits and Delusions in Schizophrenic Patients. Issues in Mental Health Nursing, 2018, 39, 269-274.	0.6	7
696	Dimensional assessment of schizotypal, psychotic, and other psychiatric traits in children and their parents: development and validation of the Childhood Oxfordâ&Liverpool Inventory of Feelings and Experiences on a representative US sample. Journal of Child Psychology and Psychiatry and Allied Disciplines. 2018. 59. 574-585.	3.1	4
697	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. Schizophrenia Research, 2018, 195, 562-563.	1.1	5
698	From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline. Journal of Psychiatric Research, 2018, 96, 231-238.	1.5	68
699	Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood. Psychopharmacology, 2018, 235, 651-661.	1.5	19
700	Spatial learning and flexibility in 129S2/SvHsd and C57BL/6J mouse strains using different variants of the Barnes maze. Behavioural Pharmacology, 2018, 29, 688-700.	0.8	8
701	Sleeping beauty syndrome presenting with insomnia. BMJ Case Reports, 2018, 2018, bcr-2018-225873.	0.2	1
702	Cognitive Impairment in Schizophrenia: Description and Cognitive Familiar Endophenotypes. A Review of the Literature. , 0, , .		3
703	Effectiveness of Integrated Neurocognitive Therapy on Cognitive Impairment and Functional Outcome for Schizophrenia Outpatients. Schizophrenia Research and Treatment, 2018, 2018, 1-9.	0.7	5
704	Assessment of the Association Between Cigarette Smoking and Cognitive Performance in Patients With Schizophrenia-Spectrum Disorders: A Case-Control Study. Frontiers in Psychiatry, 2018, 9, 642.	1.3	12
705	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry, 2018, 9, 622.	1.3	115
706	Longâ€ŧerm cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings. Acta Psychiatrica Scandinavica, 2018, 138, 591-604.	2.2	30
707	Associations Among Suicidal Ideation, White Matter Integrity and Cognitive Deficit in First-Episode Schizophrenia. Frontiers in Psychiatry, 2018, 9, 391.	1.3	43
708	Comparing cognitive clusters across first- and multiple-episode of psychosis. Psychiatry Research, 2018, 269, 707-718.	1.7	19
709	Cognitive improvement in first-episode schizophrenia and healthy controls: A 6-year multi-assessment follow-up study. Psychiatry Research, 2018, 267, 319-326.	1.7	9
710	Single transcranial direct current stimulation in schizophrenia: Randomized, cross-over study of neurocognition, social cognition, ERPs, and side effects. PLoS ONE, 2018, 13, e0197023.	1.1	24

#	Article	IF	CITATIONS
711	Neurocognitive Impairments Are More Severe in the Binge-Eating/Purging Anorexia Nervosa Subtype Than in the Restricting Subtype. Frontiers in Psychiatry, 2018, 9, 138.	1.3	18
712	The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia. Frontiers in Psychiatry, 2018, 9, 157.	1.3	103
713	Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. JAMA Psychiatry, 2018, 75, 929.	6.0	54
714	Neurocognitive dysfunction in subjects at clinical high risk for psychosis: A meta-analysis. Journal of Psychiatric Research, 2018, 103, 38-45.	1.5	42
715	Cognitive Phenotypes for Biomarker Identification in Mental Illness: Forward and Reverse Translation. Current Topics in Behavioral Neurosciences, 2018, 40, 111-166.	0.8	7
716	Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction. Behavioural Brain Research, 2018, 350, 31-43.	1.2	20
717	Assessment of Neurocognitive Functions in 7-Year-Old Children at Familial High Risk for Schizophrenia or Bipolar Disorder. JAMA Psychiatry, 2018, 75, 844.	6.0	60
718	Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. Psychological Medicine, 2019, 49, 1138-1147.	2.7	20
719	Impact of number of episodes on neurocognitive trajectory in bipolar disorder patients: a 5-year follow-up study. Psychological Medicine, 2019, 49, 1299-1307.	2.7	52
720	Impacts de la combinaison de programmes de soutien à l'emploi et de remédiation cognitive sur le maintien en emploi de personnes souffrant de schizophrénieÂ: une méta-analyse. Annales Medico-Psychologiques, 2019, 177, 534-543.	0.2	6
721	The efficacy of computerized cognitive drill and practice training for patients with a schizophrenia-spectrum disorder: A meta-analysis. Schizophrenia Research, 2019, 204, 368-374.	1.1	52
722	Maternal immune activation in mid-late gestation alters amphetamine sensitivity and object recognition, but not other schizophrenia-related behaviours in adult rats. Behavioural Brain Research, 2019, 356, 358-364.	1.2	18
723	Gene expression changes related to immune processes associate with cognitive endophenotypes of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 159-167.	2.5	8
724	Cognitive remediation in large systems of psychiatric care. CNS Spectrums, 2019, 24, 163-173.	0.7	13
725	Pathways to functional outcomes in schizophrenia spectrum disorders: Meta-analysis of social cognitive and neurocognitive predictors. Neuroscience and Biobehavioral Reviews, 2019, 105, 212-219.	2.9	145
726	Meta-analysis of cognitive function in Chinese first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment. Annals of General Psychiatry, 2019, 32, e100043.	1.1	52
727	Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study. BMC Psychiatry, 2019, 19, 220.	1.1	8
728	Physical performance is more strongly associated with cognition in schizophrenia than psychiatric symptoms. European Psychiatry, 2019, 61, 72-78.	0.1	3

#	Article	IF	CITATIONS
729	MCCB cognitive profile in Spanish first episode schizophrenia patients. Schizophrenia Research, 2019, 211, 88-92.	1.1	14
730	Acute and Transient Psychotic Disorders: Newer Understanding. Current Psychiatry Reports, 2019, 21, 113.	2.1	17
731	Circadian Clocks in the Regulation of Neurotransmitter Systems. Pharmacopsychiatry, 2019, 46, .	1.7	7
732	Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology. Psychiatry Research, 2019, 280, 112509.	1.7	19
733	Hippocampal Volume, Cognitive Functions, Depression, Anxiety, and Quality of Life in Patients With Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4563-4577.	1.8	28
734	Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes. Neuroscience and Biobehavioral Reviews, 2019, 107, 828-845.	2.9	62
735	Theory of mind in schizophrenia and bipolar disorder: psychometric properties of the Norwegian version of the Hinting Task. Cognitive Neuropsychiatry, 2019, 24, 454-469.	0.7	9
736	Factors Associated With Response and Resistance to Cognitive Remediation in Schizophrenia: A Critical Review. Frontiers in Pharmacology, 2018, 9, 1542.	1.6	19
737	High-frequency repetitive transcranial magnetic stimulation (rTMS) improves neurocognitive function in bipolar disorder. Journal of Affective Disorders, 2019, 246, 851-856.	2.0	35
738	Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study. Psychiatry Research - Neuroimaging, 2019, 290, 5-13.	0.9	7
739	Zebrafish as an Emerging Model for Bioassay-Guided Natural Product Drug Discovery for Neurological Disorders. Medicines (Basel, Switzerland), 2019, 6, 61.	0.7	28
740	Structural Covariance Reveals Alterations in Control and Salience Network Integrity in Chronic Schizophrenia. Cerebral Cortex, 2019, 29, 5269-5284.	1.6	29
741	Associations of schizophrenia risk genes ZNF804A and CACNA1C with schizotypy and modulation of attention in healthy subjects. Schizophrenia Research, 2019, 208, 67-75.	1.1	20
742	Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry, 2019, 18, 146-161.	4.8	348
743	Cognitive Profiles and Functional Connectivity in First-Episode Schizophrenia Spectrum Disorders – Linking Behavioral and Neuronal Data. Frontiers in Psychology, 2019, 10, 689.	1.1	29
744	Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacological Reports, 2019, 71, 768-773.	1.5	10
745	A Machine Learning Approach for the Automatic Classification of Schizophrenic Discourse. IEEE Access, 2019, 7, 45544-45553.	2.6	7
746	Sixth Kraepelin Symposium—Understanding and Treating Cognitive Impairment and Depression in Schizophrenia and Affective Disorders. Schizophrenia Bulletin, 2019, 45, 509-511.	2.3	3

#	Article	IF	CITATIONS
747	An integrated neurocognitive and social-cognitive treatment for youth at clinical high risk for psychosis: Cognition for Learning and for Understanding Everyday Social Situations (CLUES). Schizophrenia Research, 2019, 208, 55-59.	1.1	11
748	The validation of a new online cognitive assessment tool: The MyCognition Quotient. International Journal of Methods in Psychiatric Research, 2019, 28, e1775.	1.1	24
749	Neurophysiological Features of Perception of Roman and Arabic Numerals in Paranoid Schizophrenia Patients. Human Physiology, 2019, 45, 493-499.	0.1	1
751	Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research. Frontiers in Psychiatry, 2019, 10, 880.	1.3	28
752	Chronic nicotine administration restores brain region specific upregulation of oxytocin receptor binding levels in a G72 mouse model of schizophrenia. European Journal of Neuroscience, 2019, 50, 2255-2263.	1.2	6
753	Cognitive training improves the disturbed behavioral architecture of schizophrenia-like rats, "Wisket― Physiology and Behavior, 2019, 201, 70-82.	1.0	8
754	Neural correlates of cognitive deficits across developmental phases of schizophrenia. Neurobiology of Disease, 2019, 131, 104353.	2.1	35
755	Patterns of Nonsocial and Social Cognitive Functioning in Adults With Autism Spectrum Disorder. JAMA Psychiatry, 2019, 76, 135.	6.0	133
756	Discoidin domain receptor 1 gene variants are associated with decreased white matter fractional anisotropy and decreased processing speed in schizophrenia. Journal of Psychiatric Research, 2019, 110, 74-82.	1.5	18
757	Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 49-58.	1.8	8
758	Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. Microbial Biotechnology, 2020, 14, 106-114.	0.9	17
759	Lower [18F]fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome: a positron emission tomography study. Psychological Medicine, 2020, 50, 799-807.	2.7	2
760	Synaptic biomarker reduction and impaired cognition in the sub-chronic PCP mouse model for schizophrenia. Journal of Psychopharmacology, 2020, 34, 115-124.	2.0	14
761	Neurocognition functioning as a prerequisite to intact social cognition in schizophrenia. Cognitive Neuropsychiatry, 2020, 25, 14-27.	0.7	6
762	Characterizing functional regional homogeneity (ReHo) as a B-SNIP psychosis biomarker using traditional and machine learning approaches. Schizophrenia Research, 2020, 215, 430-438.	1.1	30
763	Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits. Schizophrenia Research, 2020, 215, 270-276.	1.1	23
764	Progression of the functional deficit in a group of patients with bipolar disorder: a cluster analysis based on longitudinal data. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 947-957.	1.8	16
765	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology, 2020, 172, 107704.	2.0	180

#	Article	IF	Citations
766	Assessing Youth with Psychotic Experiences: A Phenomenological Approach. Child and Adolescent Psychiatric Clinics of North America, 2020, 29, 1-13.	1.0	5
767	Effectiveness of integrated psychological therapy on cognitive function among Lebanese patients with schizophrenia: a pilot study. International Journal of Psychiatry in Clinical Practice, 2020, 24, 43-52.	1.2	3
768	The synergetic effect of childhood trauma and recent stressful events in psychosis: associated neurocognitive dysfunction. Acta Psychiatrica Scandinavica, 2020, 141, 43-51.	2.2	13
769	Screening for cognitive impairment in non-affective psychoses: A comparison between the SCIP and the MoCA. Schizophrenia Research, 2020, 218, 188-194.	1.1	11
770	Effect of music listening on P300 event-related potential in patients with schizophrenia: A pilot study. Schizophrenia Research, 2020, 216, 85-96.	1.1	7
771	Humor perception in schizophrenia appears to be related to disorganization syndrome. Comprehensive Psychiatry, 2020, 96, 152149.	1.5	5
772	Evaluation of social cognitive measures in an Asian schizophrenia sample. Schizophrenia Research: Cognition, 2020, 20, 100169.	0.7	12
773	The association between serum insulin-like growth factor 1 and cognitive impairments in patients with schizophrenia. Psychiatry Research, 2020, 285, 112731.	1.7	13
774	The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opinion on Drug Safety, 2020, 19, 43-57.	1.0	33
775	Autistic symptoms predict social cognitive performance in patients with schizophrenia Schizophrenia Research, 2020, 215, 113-119.	1.1	22
776	Investigating Cognitive and Clinical Predictors of Real-Life Functioning, Functional Capacity, and Quality of Life in Individuals at Ultra-High Risk for Psychosis. Schizophrenia Bulletin Open, 2020, 1, .	0.9	5
777	Semantic Search in Psychosis: Modeling Local Exploitation and Global Exploration. Schizophrenia Bulletin Open, 2020, 1, sgaa011.	0.9	14
778	Cognitive Rehabilitation and Neuroimaging. , 2020, , .		2
779	Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. Schizophrenia Research, 2020, 223, 297-304.	1.1	9
780	Emotion Recognition, Emotion Awareness, Metacognition, and Social Functioning in Persons with Schizophrenia. Indian Journal of Psychological Medicine, 2020, 42, 147-154.	0.6	7
781	Association of schizophrenia polygenic risk score with data-driven cognitive subtypes: A six-year longitudinal study in patients, siblings and controls. Schizophrenia Research, 2020, 223, 135-147.	1.1	14
782	Association of white matter microstructure and extracellular free-water with cognitive performance in the early course of schizophrenia. Psychiatry Research - Neuroimaging, 2020, 305, 111159.	0.9	12
783	Cognitive reserve in patients with first-episode psychosis as outcome predictor at 5-year follow-up. European Child and Adolescent Psychiatry, 2021, 30, 1959-1967.	2.8	9

#	Article	IF	CITATIONS
784	Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. ACS Pharmacology and Translational Science, 2020, 3, 1042-1062.	2.5	6
785	Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks. Psychological Medicine, 2022, 52, 1115-1125.	2.7	8
786	Toxoplasma gondii Effects on the Relationship of Kynurenine Pathway Metabolites to Acoustic Startle Latency in Schizophrenia vs. Control Subjects. Frontiers in Psychiatry, 2020, 11, 552743.	1.3	4
787	Modeling Social Sensory Processing During Social Computerized Cognitive Training for Psychosis Spectrum: The Resting-State Approach. Frontiers in Psychiatry, 2020, 11, 554475.	1.3	3
788	Are CB2 Receptors a New Target for Schizophrenia Treatment?. Frontiers in Psychiatry, 2020, 11, 587154.	1.3	17
789	Can Cognitive Remediation in Groups Prevent Relapses?. Journal of Nervous and Mental Disease, 2020, 208, 362-370.	0.5	4
790	Evidence-Based Integrated Intervention in Patients with Schizophrenia: A Pilot Study of Feasibility and Effectiveness in a Real-World Rehabilitation Setting. International Journal of Environmental Research and Public Health, 2020, 17, 3352.	1.2	19
791	Differences in theory of mind between early and chronic stages in schizophrenia. Journal of Psychiatric Research, 2020, 127, 35-41.	1.5	10
792	Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. Expert Opinion on Emerging Drugs, 2020, 25, 189-200.	1.0	15
793	Computer-based Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders. The Cochrane Library, 2020, , .	1.5	0
794	Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. Behavioural Brain Research, 2020, 393, 112769.	1.2	15
795	A meta-analysis comparing cognitive function across the mood/psychosis diagnostic spectrum. Psychological Medicine, 2022, 52, 323-331.	2.7	3
796	Montreal Cognitive Assessment for evaluating the cognitive impairment in patients with schizophrenia: A systematic review. General Hospital Psychiatry, 2020, 65, 64-73.	1.2	22
797	Relationships between abnormal neural activities and cognitive impairments in patients with drug-naive first-episode schizophrenia. BMC Psychiatry, 2020, 20, 283.	1.1	21
799	Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction. Journal of Neuroscience, 2020, 40, 6121-6132.	1.7	7
800	Autistic Symptoms and Social Cognition Predict Real-World Outcomes in Patients With Schizophrenia. Frontiers in Psychiatry, 2020, 11, 524.	1.3	23
801	Amphetamine-induced striatal dopamine release in schizotypal personality disorder. Psychopharmacology, 2020, 237, 2649-2659.	1.5	4
802	Predictive factors of functional outcome in patients with bipolar I disorder: a five-year follow-up. Journal of Affective Disorders, 2020, 272, 249-258.	2.0	10

#	Article	IF	CITATIONS
803	Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery. Schizophrenia Research, 2020, 218, 85-92.	1.1	13
804	Practice Effects and Test–Retest Reliability of the Continuous Performance Test, Identical Pairs Version in Patients with Schizophrenia over Four Serial Assessments. Archives of Clinical Neuropsychology, 2020, 35, 545-552.	0.3	6
805	Cognitive risk factors for psychosis. , 2020, , 269-287.		3
806	Individual Alpha Peak Frequency Moderates Transfer of Learning in Cognitive Remediation of Schizophrenia. Journal of the International Neuropsychological Society, 2020, 26, 19-30.	1.2	4
807	Relationship of poor insight to neurocognition, social cognition, and psychiatric symptoms in schizophrenia: A meta-analysis. Schizophrenia Research, 2020, 220, 164-171.	1.1	21
808	Efficacy of psychological interventions targeting cognitive biases in schizophrenia: A systematic review and meta-analysis. Clinical Psychology Review, 2020, 78, 101854.	6.0	38
809	Advancing study of cognitive impairments for antipsychotic-naÃ <sup>-</sup> ve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology. Schizophrenia Research, 2020, 220, 1-15.	1.1	6
810	Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls. NPJ Schizophrenia, 2020, 6, 8.	2.0	20
811	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. Psychiatry Research, 2020, 290, 112969.	1.7	6
812	Is that schizophrenia or frontotemporal dementia? Supporting clinicians in making the right diagnosis. Acta Neurologica Belgica, 2020, 120, 799-804.	0.5	8
813	Association between cognitive phenotype in unaffected siblings and prospective 3- and 6-year clinical outcome in their proband affected by psychosis. Psychological Medicine, 2021, 51, 1916-1926.	2.7	2
814	High-intensity interval training and active video gaming improve neurocognition in schizophrenia: a randomized controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 339-353.	1.8	16
815	Phencyclidine-induced cognitive impairments in repeated touchscreen visual reversal learning tests in rats. Behavioural Brain Research, 2021, 404, 113057.	1.2	4
816	Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia: A case-control study. Journal of Psychiatric Research, 2021, 134, 39-47.	1.5	13
817	Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. Schizophrenia Bulletin, 2021, 47, 712-721.	2.3	17
818	Predictors of remission from the ultraâ€high risk state for psychosis. Microbial Biotechnology, 2021, 15, 104-112.	0.9	8
819	Generalized neurocognitive impairment in individuals at ultraâ€high risk for psychosis: The possible key role of slowed processing speed. Brain and Behavior, 2021, 11, e01962.	1.0	10
821	Altered effective connectivity within an oculomotor control network in individuals with schizophrenia. NeuroImage: Clinical, 2021, 31, 102764.	1.4	2

#	Article	IF	CITATIONS
822	Psychosocial rehabilitation interventions in the treatment of schizophrenia and bipolar disorder. Noropsikiyatri Arsivi, 2021, 58, S77-S82.	0.2	7
823	Structural and Functional Connectivity Changes Following Cognitive Remediation: A Systematic Review. , 2021, , 371-394.		0
824	Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference. Brain and Neuroscience Advances, 2021, 5, 239821282110031.	1.8	0
825	Video games for people with schizophrenia. The Cochrane Library, 2021, 2021, CD012844.	1.5	5
826	A Network of Psychopathological, Cognitive, and Motor Symptoms in Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2021, 47, 915-926.	2.3	16
827	Education Mediates Racial Disparities in Cognitive Impairment Among Older Adults With Schizophrenia. Clinical Gerontologist, 2021, , 1-14.	1.2	3
828	Dysbindin-1 regulates mitochondrial fission and gamma oscillations. Molecular Psychiatry, 2021, 26, 4633-4651.	4.1	7
829	Functional connectivity abnormalities of the long-axis hippocampal subregions in schizophrenia during episodic memory. NPJ Schizophrenia, 2021, 7, 19.	2.0	11
830	Cognitive Predictors of Social and Occupational Functioning in Early Psychosis: A Systematic Review and Meta-analysis of Cross-Sectional and Longitudinal Data. Schizophrenia Bulletin, 2021, 47, 1243-1253.	2.3	59
832	Bifactor model of cognition in schizophrenia: Evidence for general and specific abilities. Journal of Psychiatric Research, 2021, 136, 132-139.	1.5	2
833	Improving cognition in severe mental illness by combining cognitive remediation and transcranial direct current stimulation: study protocol for a pragmatic randomized controlled pilot trial (HEADDSET). Trials, 2021, 22, 275.	0.7	1
834	Functional Connectivity During Visuospatial Processing in Schizophrenia: A Classification Study Using Lasso Regression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1077-1087.	1.0	5
836	Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Frontiers in Pharmacology, 2021, 12, 614811.	1.6	24
837	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. Schizophrenia Research, 2021, 231, 179-188.	1.1	6
838	Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder. Cognitive Neuropsychiatry, 2021, 26, 257-272.	0.7	6
839	Myospryn deficiency leads to impaired cardiac structure and function and schizophrenia-associated symptoms. Cell and Tissue Research, 2021, 385, 675-696.	1.5	3
840	Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 66-77.	2.7	8
841	Cross-cultural adaptation and validation of the Arabic version of the BACS scale (the brief) Tj ETQq1 1 0.784314 2021, 21, 223.	rgBT /Ove 1.1	rlock 10 Tf 50 11

		15	Circumon
#	ARTICLE	IF	CITATIONS
842	Schizophrenia-Like Behavioral Impairments in Mice with Suppressed Expression of Piccolo in the Medial Prefrontal Cortex. Journal of Personalized Medicine, 2021, 11, 607.	1.1	8
843	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. Revista Brasileira De Psiquiatria, 2021, , .	0.9	6
844	Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. Health Psychology Research, 2021, 9, 24932.	0.6	5
845	Assessing cognition in people with severe mental disorders in low- and middle-income countries: a systematic review of assessment measures. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 435-460.	1.6	5
847	Caffeine – treat or trigger? Disparate behavioral and long-term dopaminergic changes in control and schizophrenia-like Wisket rats. Physiology and Behavior, 2021, 236, 113410.	1.0	5
848	Social cognition in multiple sclerosis and its subtypes: A meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 52, 102973.	0.9	25
849	Altered functional connectivity of the dentate nuclei in patients with schizophrenia. Schizophrenia Research, 2021, 233, 16-23.	1.1	6
850	Rare Copy Number Variants Are Associated With Poorer Cognition in Schizophrenia. Biological Psychiatry, 2021, 90, 28-34.	0.7	20
851	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life― Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110250.	2.5	18
852	Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia. JAMA Psychiatry, 2021, 78, 848.	6.0	208
853	A Kiosk Station for the Assessment of Multiple Cognitive Domains and Cognitive Enrichment of Monkeys. Frontiers in Behavioral Neuroscience, 2021, 15, 721069.	1.0	13
854	Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague–Dawley rats exposed to glutathione deficit during early postnatal development of the brain. Pharmacological Reports, 2021, 73, 1712-1723.	1.5	3
855	"Unáhlené zÃįvÄ›ry" u psychotických onemocnÄ›nÃ <del>:</del> pÅ™ehledovÃį studie. Psychologie Pro Praxi, 20	)2 <b>..6</b> 5, 55	5-70.
856	Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 1891-1905.	2.7	3
857	Practice Effects, Test–Retest Reliability, and Minimal Detectable Change of the Ruff 2 and 7 Selective Attention Test in Patients with Schizophrenia. International Journal of Environmental Research and Public Health, 2021, 18, 9440.	1.2	1
858	Altered Effective Connectivity within an Oculomotor Control Network in Unaffected Relatives of Individuals with Schizophrenia. Brain Sciences, 2021, 11, 1228.	1.1	1
859	Let's lower the floor: clinical utility of the D-KEFS TMT with a forensic psychiatric inpatient population. Applied Neuropsychology Adult, 2021, , 1-9.	0.7	0
860	Effects of IPS plus cognitive remediation in early psychosis: 18-month functioning outcomes of a randomized controlled trial. Schizophrenia Research, 2021, 236, 115-122.	1.1	7

#	Article	IF	CITATIONS
861	Early and middle latency auditory event-related potentials do not explain differences in neuropsychological performance between schizophrenia spectrum patients and matched healthy controls. Psychiatry Research, 2021, 304, 114162.	1.7	2
862	Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. Schizophrenia Research, 2021, 236, 54-60.	1.1	2
863	Basal ganglia shape features differentiate schizoaffective disorder from schizophrenia. Psychiatry Research - Neuroimaging, 2021, 317, 111352.	0.9	5
864	Network analysis of cognitive deficit in patients with schizophrenia spectrum disorders. Schizophrenia Research: Cognition, 2021, 26, 100213.	0.7	10
865	The association between smoking behaviour, social cognition and social functioning in patients with a non-affective psychotic disorder: A prospective follow-up study. Schizophrenia Research: Cognition, 2021, 26, 100206.	0.7	2
866	The relationship between cognition and functioning in schizophrenia: A semi-systematic review. Schizophrenia Research: Cognition, 2022, 27, 100217.	0.7	32
867	The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry, 2021, 20, 4-33.	4.8	153
868	Selective noradrenaline reuptake inhibitors for schizophrenia. The Cochrane Library, 0, , .	1.5	1
870	How Behavioral Healthcare Informatics Systems Interface with Medical Informatics Systems: A Work in Progress. Computers in Health Care, 2010, , 195-204.	0.2	2
871	Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging. , 2014, , 465-512.		4
872	Neurological and Neuropsychological Endophenotypes in Schizophrenia Spectrum Disorders. , 2011, , 325-349.		2
873	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia. , 2011, , 33-74.		1
874	Developmental Consequences of Prenatal Exposure to Maternal Immune Activation. , 2011, , 263-285.		1
875	Genetic Rat Models for Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 303-324.	0.7	4
876	Sexual Dimorphisms in Psychosis Risk: A Neurodevelopmental Perspective. , 2016, , 107-127.		3
877	Modelo predictivo de la funcionalidad en la esquizofrenia: una aproximación desde el modelado de ecuaciones estructurales. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 232-241.	1.0	8
878	Default mode functional connectivity is associated with social functioning in schizophrenia Journal of Abnormal Psychology, 2017, 126, 392-405.	2.0	45
879	Effects of the CACNA1C risk allele on neurocognition in patients with schizophrenia and healthy individuals. Scientific Reports, 2012, 2, 634.	1.6	39

#	Article	IF	CITATIONS
880	Cognitive impairment in schizophrenia and depression: A comparison of stability and course. Applied Neuropsychology Adult, 2019, 26, 215-228.	0.7	17
882	Disintegration of social cognitive processes in schizophrenia. Psychiatria Polska, 2013, 47, 1023-1039.	0.2	3
883	Effects of the Selective 5-HT7 Receptor Antagonist SB-269970 and Amisulpride on Ketamine-Induced Schizophrenia-like Deficits in Rats. PLoS ONE, 2013, 8, e66695.	1.1	89
884	Inflexible Minds: Impaired Attention Switching in Recent-Onset Schizophrenia. PLoS ONE, 2013, 8, e78062.	1.1	10
885	The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement. PLoS ONE, 2016, 11, e0167390.	1.1	18
886	Association of a risk allele of ANK3 with cognitive performance and cortical thickness in patients with first-episode psychosis. Journal of Psychiatry and Neuroscience, 2014, 39, 31-39.	1.4	32
887	Confiabilidade dos Ãndices Fatoriais da Wais-III Adaptada para a População Brasileira. Psicologia - Teoria E Prática, 2015, 17, 123-139.	0.0	6
888	Alterações cognitivas na esquizofrenia: atualização. Revista De Psiquiatria Do Rio Grande Do Sul, 2010, 32, 57-63.	0.3	7
889	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. Journal of Psychiatry and Brain Science, 2019, 4, .	0.3	9
890	Social Cognition, Negative Symptoms and Psychosocial Functioning in Schizophrenia. International Journal of Clinical Neurosciences and Mental Health, 2016, , 1.	0.7	10
891	Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia. Current Pharmaceutical Design, 2014, 20, 5077-5092.	0.9	25
892	Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis. Current Neuropharmacology, 2016, 14, 272-281.	1.4	36
893	Cognitive training in virtual reality vs. cogpack in patients with schizophrenia: study proposal. Minerva Psichiatrica: A Journal on Psychiatry, Psychology and Psychopharmacology, 2020, 61, .	0.6	1
894	Evaluating the feasibility of the Italian version of the computerized interactive remediation of cognition training for schizophrenia (CIRCuiTS). Minerva Psichiatrica: A Journal on Psychiatry, Psychology and Psychopharmacology, 2020, 61, .	0.6	1
895	Life Course Challenges Faced by Siblings of Individuals with Schizophrenia May Increase Risk for Depressive Symptoms. Mental Health in Family Medicine, 2016, 12, 147-151.	0.2	10
897	Neurocognitive Findings in Bipolar Disorder. Medical Psychiatry, 2007, , 251-274.	0.2	1
898	Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. Dialogues in Clinical Neuroscience, 2006, 8, 9-16.	1.8	62
899	The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues in Clinical Neuroscience, 2006, 8, 109-113.	1.8	62

#	Article	IF	CITATIONS
900	Executive control: balancing stability and flexibility via the duality of evolutionary neuroanatomical trends. Dialogues in Clinical Neuroscience, 2012, 14, 39-47.	1.8	15
901	Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues in Clinical Neuroscience, 2019, 21, 239-248.	1.8	117
903	Poor Premorbid Adjustment and Dysfunctional Executive Abilities Predict Theory of Mind Deficits in Stabilized Schizophrenic Outpatients. Clinical Schizophrenia and Related Psychoses, 2008, 2, 205-216.	1.4	4
904	Social Cognitive Markers of Short-Term Clinical Outcome in First-Episode Psychosis. Clinical Schizophrenia and Related Psychoses, 2010, 4, 105-114.	1.4	17
905	Cognitive effects of atypical antipsychotic drugs in first-episode drug-naÃ⁻ve schizophrenic patients. Neural Regeneration Research, 2013, 8, 277-86.	1.6	20
906	Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder. Journal of Clinical Psychiatry, 2006, 67, e12.	1.1	461
907	The early longitudinal course of cognitive deficits in schizophrenia. Journal of Clinical Psychiatry, 2014, 75 Suppl 2, 25-9.	1.1	37
908	Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 1186-1194.	1.1	42
909	Executive function in patients with schizophrenia based on socio-occupational impairment: A cross-sectional study. Industrial Psychiatry, 2018, 27, 181.	0.3	5
910	The social neuroscience of psychosis: From neurobiology to neurotherapeutics. Indian Journal of Psychiatry, 2020, 62, 470.	0.4	1
911	Subjective cognitive complaints and its relation to objective cognitive performance, clinical profile, clinical insight, and social functioning in patients of schizophrenia: A cross-sectional study. Indian Journal of Psychiatry, 2020, 62, 178.	0.4	10
912	Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials. European Journal of Psychiatry, 2009, 23, .	0.7	15
913	Cognitive Profile Difference Between Allen Cognitive Levels 4 and 5 in Schizophrenia. American Journal of Occupational Therapy, 2011, 65, 453-461.	0.1	12
914	How Reversible is Social Dysfunction in Autistic Spectrum Disorders?. North American Journal of Medicine & Science, 2012, 5, 172.	3.8	1
915	Brain Activation Patterns Associated with the Effects of Fearful Distractors during Working Memory Maintenance in Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2019, 17, 54-63.	0.9	1
916	Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/Computerized Tomography Investigation. Clinical Psychopharmacology and Neuroscience, 2019, 17, 250-260.	0.9	16
917	Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: A randomized controlled trial. Schizophrenia Research, 2021, 238, 108-120.	1.1	27
918	Neurocognitive Findings in Bipolar Disorder. , 2007, , 265-288.		0

#	Article	IF	CITATIONS
919	Avaliação neuropsicológica na esquizofrenia: revisão sistemática. Revista De Psiquiatria Do Rio Grande Do Sul, 2008, 30, .	0.3	0
920	Computer-based Cognitive and Socio-emotional Training in Psychopathology. , 0, , .		0
921	Attention and Working Memory: Animal Models for Cognitive Symptoms of Schizophrenia – Studies on D2-Like Receptor Knockout Mice. , 2009, , 501-512.		0
922	The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic Studies of Schizophrenia. , 2009, , 177-193.		0
923	Schizophrenia as a Cognitive Disorder: Recent Approaches to Identifying its Core Cognitive Components to Aid Treatment Development. , 2010, , 267-282.		0
924	Diagnosis of Complex Diseases. , 2010, , 347-382.		0
927	Cognitive Impairments in Schizophrenia and Psychotic Bipolar Disorder and Their Relation to Psychotic Symptoms. The Korean Journal of Clinical Psychology, 2010, 29, 471-489.	0.3	1
928	8. RECOSÂ: un programme adapté au profil cognitif des patients schizophrènes. , 2011, , 225-247.		0
929	Contexte. , 2012, , 12-90.		0
930	Mentalizing Skills Deficits in Schizophrenia as a Clue for Drug Choice: Clozapine Versus Other Antipsychotics on Keeping Outpatients Stable. , 0, , .		0
931	I disturbi cognitivi nella schizofrenia. , 2013, , 3-12.		0
933	Cogpack®: prove di efficacia. , 2013, , 161-167.		0
935	Therapievoraussetzungen, Einsatzm $ ilde{A}$ ¶glichkeiten und Indikation. , 2013, , 125-130.		0
936	Douleur et schizophrénie : quand l'esprit ignore les appels grandissants de la moelle. , 2013, , 111-128.		1
937	Praktische Durchführung der INT. , 2013, , 13-123.		0
938	Tecniche di rimedio cognitivo nella schizofrenia: ambiti di intervento ed evidenze di efficacia. , 2013, , 125-147.		0
939	Could Schizophrenia Be a Refractory Condition to Central Pain Sensitization?. , 2014, , 157-171.		0
940	K-WAIS-⣠Profile in Schizophrenia. The Korean Journal of Clinical Psychology, 2014, 33, 719-734.	0.3	2

#	Article	IF	CITATIONS
942	Fondamenti teorici. , 2015, , 1-18.		0
943	Therapy Requirements, Possible Applications, and Indication. , 2015, , 115-120.		0
945	Practical Implementation of INT. , 2015, , 13-114.		0
946	INT: applicazione pratica. , 2015, , 19-216.		0
948	Is There More to Insight Into Illness in Schizophrenia Than Cognition? A Study Applying the Dynamic Wisconsin Card Sorting Test. Journal of Cognitive Education and Psychology, 2017, 16, 94-106.	0.2	0
949	Alteraciones neurocognitivas en la esquizofrenia. Análisis factorial. Medicina UPB, 2017, 36, 123-132.	0.1	2
950	Dynamic Assessment of a Schizophrenic Foreign Language Learner. Iranian Rehabilitation Journal, 2017, 15, 341-350.	0.1	0
951	COGNITIVE DETERMINANTS OF REAL WORLD SOCIAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 2752-2759.	0.0	0
952	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2020, , 1-56.		0
955	Cognición social en pacientes con un primer episodio psicótico. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.0	0
958	The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach. Handbook of Experimental Pharmacology, 2020, 271, 525-546.	0.9	3
960	Relating diffusion-weighted magnetic resonance imaging of brain white matter to cognitive processing-speed deficits in schizophrenia. Biomedical Physics and Engineering Express, 2020, 6, 055007.	0.6	1
963	Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. Journal of Psychiatry and Neuroscience, 2006, 31, 369-76.	1.4	35
966	Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Discovery Medicine, 2012, 14, 335-43.	0.5	31
968	Symptom severity is more closely associated with social functioning status in inpatients with schizophrenia than cognitive deficits. Shanghai Archives of Psychiatry, 2012, 24, 83-90.	0.7	0
969	Cognitive functions in methamphetamine induced psychosis compared to schizophrenia and normal subjects. Iranian Journal of Psychiatry, 2014, 9, 152-7.	0.4	11
971	Exploring the associations of herpes simplex virus infection and cognitive dysfunction in schizophrenia: Studies in India. Indian Journal of Psychiatry, 2018, 60, 393-397.	0.4	0
972	People with schizophrenia do not show the normal benefits of social versus nonsocial attentional cues. Neuropsychology, 2020, 34, 620-628.	1.0	0

#	Article	IF	CITATIONS
973	Structural brain correlates of cognitive function in schizophrenia: A meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 132, 37-49.	2.9	33
974	Validity of remote administration of the MATRICS Consensus Cognitive Battery for individuals with severe mental illness. Schizophrenia Research: Cognition, 2021, 27, 100226.	0.7	2
975	A review of risky decision-making in psychosis-spectrum disorders. Clinical Psychology Review, 2022, 91, 102112.	6.0	12
976	Neurocognition, functional outcome, and quality of life in remitted and non-remitted schizophrenia: A comparison with euthymic bipolar I disorder and a control group Schizophrenia Research, 2022, 240, 81-91.	1.1	2
977	Prevalence, profile and associations of cognitive impairment in Ugandan first-episode psychosis patients. Schizophrenia Research: Cognition, 2022, 28, 100234.	0.7	2
978	Chapitre 1. Schizophrénie(s)Â: cliniques. , 2015, , 5-18.		0
979	People with schizophrenia do not show the normal benefits of social versus nonsocial attentional cues Neuropsychology, 2020, 34, 620-628.	1.0	3
980	Sheltered employment in schizophrenia is related to disorganization symptoms, processing speed and metaphor comprehension. Psychiatria Polska, 2020, 54, 935-950.	0.2	1
981	Lifespan evolution of neurocognitive impairment in schizophrenia - A narrative review. Schizophrenia Research: Cognition, 2022, 28, 100237.	0.7	13
982	A family study on first episode of psychosis patients: Exploring neuropsychological performance as an endophenotype. Acta Psychiatrica Scandinavica, 2022, 145, 384-396.	2.2	6
983	Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients. Psychological Medicine, 2022, 52, 614-624.	2.7	22
984	Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis. Journal of Affective Disorders, 2022, 304, 59-65.	2.0	5
985	Web-Based Cognitive Testing in Psychiatric Research: Validation and Usability Study. Journal of Medical Internet Research, 2022, 24, e28233.	2.1	7
986	Aberrant cortical surface and cognition function in drug-naive first-episode schizophrenia. Annals of General Psychiatry, 2022, 21, 4.	1.2	3
987	Evidence of validity and reliability of the Spanish version of the "Observable Social Cognition: A Rating Scale" (OSCARS) in patients with schizophrenia. Actas Espanolas De Psiquiatria, 2021, 49, 253-268.	0.1	0
988	Occupational Therapy in Severe Mental Disorder—A Self-Controlled Quasi-Experimental Study. Healthcare (Switzerland), 2022, 10, 493.	1.0	1
989	Neuropathways of theory of mind in schizophrenia: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 137, 104625.	2.9	12
990	The relationships between cognitive reserve, cognitive functioning and quality of life in first-episode schizophrenia spectrum disorders. Psychiatry Research, 2022, 310, 114479.	1.7	4

#	Article	IF	CITATIONS
991	Detection of Schizophrenia Cases From Healthy Controls With Combination of Neurocognitive and Electrophysiological Features. Frontiers in Psychiatry, 2022, 13, 810362.	1.3	3
992	Emotional Processing Profile in Patients with First Episode Schizophrenia: The Influence of Neurocognition. Journal of Clinical Medicine, 2022, 11, 2044.	1.0	1
993	The Effect of Glutathione Deficit During Early Postnatal Brain Development on the Prepulse Inhibition and Monoamine Levels in Brain Structures of Adult Sprague–Dawley Rats. Neurotoxicity Research, 2022, , 1.	1.3	0
994	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. Cognitive Neuropsychiatry, 2022, 27, 49-68.	0.7	2
995	We Should Improve Personalization of Management in Patients with a Diagnosis of Schizophrenia. Journal of Clinical Medicine, 2022, 11, 184.	1.0	6
996	Impact of Psychosocial Occupational Therapy Combined with Anodal Transcranial Direct Current Stimulation to the Left Dorsolateral Prefrontal Cortex on the Cognitive Performance of Patients with Schizophrenia: A Randomized Controlled Trial. Hong Kong Journal of Occupational Therapy, 2021, 34. 121-131.	0.2	3
997	Thalamic Shape Abnormalities Differentially Relate to Cognitive Performance in Early-Onset and Adult-Onset Schizophrenia. Frontiers in Psychiatry, 2022, 13, 803234.	1.3	1
1007	Experimental Research. , 0, , 449-489.		0
1009	Exploring the associations of herpes simplex virus infection and cognitive dysfunction in schizophrenia: Studies in India. Indian Journal of Psychiatry, 2018, 60, 393.	0.4	3
1010	Reduced temporal activation during a verbal fluency test in clinical high risk of psychosis: a functional near-infrared spectroscopy-based study. Annals of General Psychiatry, 2022, 35, e100702.	1.1	3
1011	The Relationship Between the Recognition of Basic Emotions and Negative Symptoms in Individuals With Schizophrenia Spectrum Disorders – An Exploratory Study. Frontiers in Psychiatry, 2022, 13, 865226.	1.3	3
1012	Global functioning, cognitive function, psychopathological symptoms in untreated patients with first-episode schizophrenia: A cross-sectional study. Psychiatry Research, 2022, 313, 114616.	1.7	3
1013	The effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naÃ⁻ve, first episode schizophrenia patients. Psychiatry Research, 2022, 313, 114582.	1.7	12
1014	Examining the association of life course neurocognitive ability with real-world functioning in schizophrenia-spectrum disorders. Schizophrenia Research: Cognition, 2022, 29, 100254.	0.7	3
1016	Cognitive impairment in people with schizophrenia: an umbrella review. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1139-1155.	1.8	47
1017	The Potential Paradoxical Neurocognitive Effects of Cannabis Use in Patients with Psychotic Disorders: A Critical Meta-Review of Meta-Analytical Evidence. Cannabis and Cannabinoid Research, 0, ,	1.5	0
1018	Neurocognitive Changes in Sickle Cell Disease: A Comprehensive Review. Annals of Neurosciences, 0, , 097275312211088.	0.9	3
1019	Effects of transcranial direct current stimulation on brain changes and relation to cognition in patients with schizophrenia: a fMRI study. Brain Imaging and Behavior, 0, , .	1.1	Ο

#	Article	IF	CITATIONS
1020	Brain Stimulation and Group Therapy to Improve Gesture and Social Skills in Schizophrenia—The Study Protocol of a Randomized, Sham-Controlled, Three-Arm, Double-Blind Trial. Frontiers in Psychiatry, 0, 13, .	1.3	1
1021	The Chinese Brief Cognitive Test: Normative Data Stratified by Gender, Age and Education. Frontiers in Psychiatry, 0, 13, .	1.3	5
1022	New drug targets in psychiatry: Neurobiological considerations in the genomics era. Neuroscience and Biobehavioral Reviews, 2022, 139, 104763.	2.9	1
1023	Dimensionality analysis of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G). Schizophrenia Research: Cognition, 2022, 29, 100259.	0.7	2
1025	Associations of cognitive impairment in patients with schizophrenia with genetic features and with schizophrenia-related structural and functional brain changes. Frontiers in Genetics, 0, 13, .	1.1	1
1026	Clustering of cognitive phenotypes identifies susceptible and resilient offspring in a rat model of maternal immune activation and early-life stress. Brain, Behavior, & Immunity - Health, 2022, 25, 100514.	1.3	4
1027	Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. Advances in Experimental Medicine and Biology, 2022, , 89-103.	0.8	3
1028	European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. European Psychiatry, 2022, 65, .	0.1	37
1029	European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. European Psychiatry, 2022, 65, .	0.1	19
1030	Cognitive trajectories following onset of psychosis: a meta-analysis. British Journal of Psychiatry, 2022, 221, 714-721.	1.7	12
1031	Building a neurocognitive profile of suicidal risk in severe mental disorders. BMC Psychiatry, 2022, 22, .	1.1	4
1032	Premorbid adjustment associates with cognitive and functional deficits in individuals at ultra-high risk of psychosis. , 2022, 8, .		2
1033	Identifying and revealing different brain neural activities of cognitive subtypes in early course schizophrenia. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	3
1034	Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting. Psychiatry Research, 2022, 317, 114878.	1.7	3
1035	The MATRICS Consensus Cognitive Battery: An Update. Current Topics in Behavioral Neurosciences, 2022, , 1-18.	0.8	2
1036	Lessons Learned From Parsing Genetic Risk for Schizophrenia Into Biological Pathways. Biological Psychiatry, 2023, 94, 121-130.	0.7	8
1037	Cognitive impairments in schizophrenia and their impact on oxidative stress. V M Bekhterev Review of Psychiatry and Medical Psychology, 2022, 56, 66-79.	0.1	0
1038	A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages. Psychiatry Research, 2022, 317, 114926.	1.7	1

#	Article	IF	CITATIONS
1039	The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 121, 110668.	2.5	30
1040	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2022, , 305-359.		0
1041	Smoking Addiction in Patients with Schizophrenia Spectrum Disorders and Its Perception and Intervention in Healthcare Personnel Assigned to Psycho-Rehabilitation Programs: A Qualitative Research. Healthcare (Switzerland), 2022, 10, 2275.	1.0	1
1043	Association between motivation and engagement with changes in cognition and symptoms after digital cognitive training in schizophrenia. Schizophrenia Research, 2023, 251, 1-9.	1.1	1
1044	Cross-sectional and longitudinal assessment of the association between DDR1 variants and processing speed in patients with early psychosis and healthy controls. Journal of Psychiatric Research, 2023, 158, 49-55.	1.5	2
1045	Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study. European Neuropsychopharmacology, 2023, 67, 53-65.	0.3	0
1046	Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients. Schizophrenia Research: Cognition, 2023, 32, 100276.	0.7	0
1047	Factors Impacting Access and Engagement of Cognitive Remediation Therapy for People with Schizophrenia: A Systematic Review. Canadian Journal of Psychiatry, 2023, 68, 139-151.	0.9	7
1048	Histone Deacetylase Inhibitors As Cognitive Enhancers And Modifiers Of Mood And Behavior. Current Drug Targets, 2022, 24, .	1.0	4
1049	Does social cognition change? Evidence after 4Âyears from the Italian Network for Research on Psychoses. European Psychiatry, 2023, 66, .	0.1	2
1050	P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naÃ <sup>-</sup> ve schizophrenia. Journal of Affective Disorders, 2023, 324, 153-161.	2.0	1
1051	Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia. BMC Psychiatry, 2023, 23, .	1.1	8
1052	Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia. Brain Sciences, 2023, 13, 215.	1.1	3
1053	Changes in neurofilament light chain protein (NEFL) in children and adolescents with Schizophrenia and Bipolar Disorder: Early period neurodegeneration. Journal of Psychiatric Research, 2023, 161, 342-347.	1.5	5
1054	Toward a New, Improved Paradigm for Experimental Psychopathology Research … Or What We Would Talk About with Scott Over Coffee in a Dinkytown Cafe. , 2022, , 175-196.		0
1055	Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Molecular Psychiatry, 2023, 28, 1902-1918.	4.1	63
1056	Association of serum homocysteine levels with intestinal flora and cognitive function in schizophrenia. Journal of Psychiatric Research, 2023, 159, 258-265.	1.5	2
1057	Visual processing deficits in patients with schizophrenia spectrum and bipolar disorders and associations with psychotic symptoms, and intellectual abilities. Heliyon, 2023, 9, e13354.	1.4	1

#	Article	IF	CITATIONS
1058	Cognitive functioning in early-onset psychosis. , 2023, , 127-152.		0
1059	Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis. Systematic Reviews, 2023, 12, .	2.5	2
1061	Place de laÂremédiation cognitive dansÂleÂdispositif deÂsoins. , 2023, , 15-36.		0
1063	Neuropsychological and Functional Assessment of Cognitive Impairments in Schizophrenia. Methods in Molecular Biology, 2023, , 127-139.	0.4	0
1068	Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches toÂinsights of susceptibility genes. Metabolic Brain Disease, 0, , .	1.4	0
1077	Psychosis superspectrum I: Nosology, etiology, and lifespan development. Molecular Psychiatry, 0, , .	4.1	1